vVARDIS proposes 8.33M-share IPO at $21–$24 a share
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
vVARDIS Holding AG (VVVV) is offering 8,333,334 Class A ordinary shares in a proposed IPO; sales may begin only after the registration statement becomes effective. Underwriters may buy up to 1,250,000 additional shares within 30 days to cover over-allotments.
The expected IPO price is $21.00–$24.00 per share. At the assumed $22.50 midpoint, estimated net proceeds are $166.2 million, or $192.3 million if the option is exercised in full. Proceeds are intended for general corporate purposes, including working capital, operating expenses and capital expenditures, with possible acquisitions or strategic investments. After the offering, the founders are expected to hold 87.6% of voting power, assuming no option exercise; Class B shares carry ten times the voting power of Class A shares on a per-par-value basis.
For the nine months ended September 30, 2026, management preliminarily estimates revenue of $47.7 million to $49.2 million, up 114.0% to 120.8% from $22.287 million a year earlier. The estimated adjusted EBITDA loss is $9.2 million to $9.4 million, compared with $17.127 million; estimated net loss is $39.7 million to $41.3 million, versus $40.671 million. These estimates are unaudited, and closing procedures were incomplete.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointPreliminary nine-month revenue: $47.7–$49.2 million, up 114.0%–120.8% year over year.
- Moderate pointPreliminary adjusted EBITDA loss: $9.2–$9.4 million, versus $17.127 million a year earlier.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Founders are expected to hold 87.6% of post-offering voting power, assuming no over-allotment exercise.
Filing Explained
In the still-proposed IPO, Class B preferred holders have a right to subscribe at par for 4,498,951 additional Class A shares at the
Key Figures
Key Terms
over-allotment option financial
Adjusted EBITDA financial
dual-class share structure technical
anti-dilution rights financial
foreign private issuer regulatory
controlled company regulatory
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many shares is VVVV offering in its IPO?
How much net proceeds does vVARDIS expect from its IPO?
How do VVVV's Class A and Class B shares differ?
What drove VVVV's preliminary revenue growth?
AI-generated analysis. How Rhea-AI works. Not financial advice.
TABLE OF CONTENTS
Switzerland | 3841 | Not Applicable | ||||
(State or Other Jurisdiction of Incorporation or Organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) | ||||
Yasin Keshvargar Deanna L. Kirkpatrick Maxim Van de moortel Davis Polk & Wardwell LLP 450 Lexington Avenue New York, New York 10017 United States of America +1 212 450 4000 | Dieter Gericke Daniel Häusermann Estelle Piccard Homburger AG Hardstrasse 201 CH-8005 Zurich Switzerland +41 43 222 1000 | Patrick Schärli Stephan Erni Lenz & Staehelin Brandschenkestrasse 24 CH-8027 Zurich Switzerland +41 58 450 8000 | Brian K. Rosenzweig Matthew T. Gehl Mark Edlund Covington & Burling LLP 30 Hudson Yards New York, New York 10001 United States of America +1 212 841 1000 | ||||||
TABLE OF CONTENTS

Per Class A ordinary share | Total | |||||
Public offering price | $ | $ | ||||
Underwriting discounts and commissions(1) | $ | $ | ||||
Proceeds, before expenses, to us | $ | $ |
(1) | We have agreed to reimburse the underwriters for certain expenses in connection with this offering. See “Underwriting” for a description of all compensation payable to the underwriters. |
Joint Bookrunning Managers | |||
Goldman Sachs & Co. LLC | J.P. Morgan | ||
Bookrunners | ||||||
William Blair | UBS Investment Bank | Deutsche Bank Securities | ||||
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS | ii | ||
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS | vi | ||
SUMMARY | 1 | ||
THE OFFERING | 13 | ||
SUMMARY FINANCIAL AND OTHER INFORMATION | 17 | ||
RISK FACTORS | 21 | ||
USE OF PROCEEDS | 88 | ||
DIVIDEND POLICY | 89 | ||
CAPITALIZATION | 90 | ||
DILUTION | 94 | ||
A LETTER FROM OUR FOUNDERS | 97 | ||
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 100 | ||
BUSINESS | 123 | ||
MANAGEMENT | 161 | ||
PRINCIPAL SHAREHOLDERS | 170 | ||
RELATED PARTY TRANSACTIONS | 174 | ||
DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION | 176 | ||
COMPARISON OF SWISS CORPORATE LAW AND U.S. CORPORATE LAW | 191 | ||
ORDINARY SHARES ELIGIBLE FOR FUTURE SALE | 201 | ||
TAXATION | 203 | ||
UNDERWRITING | 210 | ||
EXPENSES OF THE OFFERING | 219 | ||
LEGAL MATTERS | 219 | ||
EXPERTS | 219 | ||
ENFORCEMENT OF JUDGMENTS | 220 | ||
WHERE YOU CAN FIND MORE INFORMATION | 221 | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | F-1 | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Skeie et al. (2022), a large-scale review combining data from multiple studies across approximately 84,512 participants, which found a 77% prevalence of early-stage cavities and included dental X-rays to assess surfaces between the teeth, where most early-stage cavities occur; |
• | Agustsdottir et al. (2010), which reported 85% prevalence in children; |
• | Rødseth et al. (2023), which reported 85.8% prevalence in adults; and |
• | Autio-Gold et al. (2005), a U.S. study of 221 children aged 5-6 that included dental X-rays for surfaces between the teeth and reported 71% prevalence in children in the United States. |
• | Autio-Gold et al. (2005), which reported an average of 2.91 early-stage cavities per affected child. Because children aged 5-6 have only 20 teeth compared to 32 in a full adult set, we normalized this figure to a 32-tooth equivalent, yielding 4.66 cavities on a comparable basis; |
• | Agustsdottir et al. (2010), which reported 5.67 cavities in 12-year-olds and 10.66 in 15-year-olds; and |
• | Rødseth et al. (2023), which reported 3.80 cavities in adults. |
TABLE OF CONTENTS
TABLE OF CONTENTS
• | demand for our Curodont® products, technologies and treatment solutions; |
• | our assumptions regarding market growth, customer and patient demand as well as adoption and penetration rates; |
• | our ability to expand and retain our network of dental professionals, distributors and strategic partners; |
• | our ability to compete effectively in the highly competitive dental products market; |
• | our ability to meet our performance and financial obligations to our contractual counterparties, including our distributors; |
• | the ability and willingness of our contractual counterparties, including our distributors and other customers, to meet their payment and other obligations to us; |
• | our ability to collect amounts owed to us under our accounts receivable; |
• | our ability to innovate and successfully expand our Curodont® technology platform and introduce new products, technologies and treatment solutions; |
• | our ability to raise awareness of our Curodont® technology platform and its clinical and commercial benefits among dental professionals and patients; |
• | the personal indebtedness of our Co-Founders and Co-CEOs and such persons’ plans to repay such indebtedness; |
• | trends affecting consumer discretionary spending and patient willingness to pursue elective dental procedures; |
• | our plans to expand our sales force and execute successfully on our sales and marketing initiatives; |
• | our ability to maintain, protect and enforce our intellectual property rights and proprietary technology; |
• | our dependence on key suppliers, manufacturers and third-party service providers; |
• | our manufacturing, supply chain, fulfillment or distribution operations; |
• | our ability to obtain, maintain and comply with applicable regulatory approvals, certifications and clearances; |
• | the impact of healthcare laws, regulations, reimbursement practices and regulatory enforcement actions; |
• | our international operations and ability to expand in existing and new geographic markets; |
• | fluctuations in foreign currency exchange rates and macroeconomic conditions; |
• | our ability to attract, retain and incentivize qualified management, clinical, technical and other personnel; |
• | the use of artificial intelligence (“AI”), machine learning (“ML”) automation and digital tools in our products and operations; |
• | our ability to manage growth effectively and scale our operations and infrastructure; |
TABLE OF CONTENTS
• | the impact of cybersecurity incidents, system failures and interruptions to our information technology systems; |
• | our ability to achieve and sustain profitability and generate positive cash flow; |
• | the impact of public health crises, geopolitical instability, inflationary pressures and other adverse global economic conditions on our business and results of operations; |
• | the effect of our multi-class share capital structure; and |
• | our anticipated use of the net proceeds from this offering. |
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Patient-friendly: needle-free, drill-free and pain-free |
• | Non-invasive: natural tooth structure is preserved |
• | Clinically validated: extensive clinical evidence supporting performance and tolerability |
• | Efficient: up to five-minute treatment duration and single visit procedure |
• | Affordable: comparable treatment cost to small, single-surface “drill-and-fill” procedure, with the potential to minimize future costs associated with increasingly invasive procedures |
• | New, billable treatment option: alternative to the current treatment options for early-stage cavities (“watch-and-wait” and “drill-and-fill”) |
• | Efficient: up to five-minute treatment duration and single-visit procedure, reducing “no show” follow-up appointments |
• | Economical: quicker treatment that allows higher revenue per hour of chair time than conventional treatment options |
• | Simple-to-use technology: can be performed by a hygienist and requires no extensive or specialized training beyond standard clinical competencies |
• | Patient compliance: supports greater patient retention and visit frequency |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Pioneering a paradigm shift in treating the world’s most prevalent non-communicable disease: tooth decay |
• | Large global market opportunity addressing a significant unmet clinical and patient need |
• | Establishing a new category with a compelling value proposition for patients, dental practitioners and payors |
• | Extensive and robust body of scientific evidence supports adoption |
• | Platform technology protected by a broad intellectual property estate and significant know-how |
• | Visionary Founders with a proven track record of value creation and rooted in clinical practice, education and scientific innovation |
• | Continue to build a commercialization infrastructure with specialized direct sales, clinical education and marketing teams that support a strategic distributor partnership in the United States |
• | Promote awareness among dental practitioners, patients and payors to accelerate adoption of Curodont® |
• | Capitalize on the growing adoption of AI-driven technology to expand the market opportunity of Curodont® in dental practices |
• | Expand our global commercial footprint |
• | Continue leveraging our Curodont® technology platform to further expand our product offering |
TABLE OF CONTENTS
Nine Months Ended September 30, | |||||||||
2026 (Estimated) | 2025 | ||||||||
(thousands of $) | High | Low | Actual | ||||||
U.S. GAAP financial measures: | |||||||||
Net revenue | 49,200 | 47,700 | 22,287 | ||||||
Gross profit | 42,300 | 41,100 | 15,378 | ||||||
Gross profit margin | 86.0% | 86.2% | 69.0% | ||||||
Net loss | (39,700) | (41,300) | (40,671) | ||||||
Non-GAAP financial measures: | |||||||||
Adjusted EBITDA(1) | (9,200) | (9,400) | (17,127) | ||||||
(1) | See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures” for the definition of Adjusted EBITDA. |
TABLE OF CONTENTS
Nine Months Ended September 30, | |||||||||
2026 (Estimated) | 2025 | ||||||||
(thousands of $) | High | Low | Actual | ||||||
Net loss | (39,700) | (41,300) | (40,671) | ||||||
Add: | |||||||||
Interest expense | 13,800 | 14,100 | 7,136 | ||||||
Income tax (benefit) / expense | — | — | (277) | ||||||
Depreciation and amortization | 3,400 | 3,400 | 2,818 | ||||||
Share-based compensation expenses | 5,500 | 5,800 | 9,917 | ||||||
Restructuring and other advisory costs(1) | 2,200 | 2,300 | — | ||||||
Loss on term loan extinguishment | 1,600 | 1,600 | 1,280 | ||||||
Loss on loans measured at fair value | 1,200 | 1,200 | 2,205 | ||||||
Gain on loan conversion | (1,600) | (1,600) | — | ||||||
Loss due to change in the fair value of derivative liabilities | 2,300 | 2,500 | — | ||||||
Foreign exchange losses(2) | 2,100 | 2,600 | 465 | ||||||
Adjusted EBITDA | (9,200) | (9,400) | (17,127) | ||||||
(1) | Represents costs incurred in connection with restructuring initiatives, including legal, advisory and employee-related costs, as well as advisory costs related to other strategic activities. |
(2) | Represents foreign exchange gains and losses, recorded within Other income/(expense) line item of consolidated statements of operation, arising from the remeasurement of non-functional currency denominated monetary assets and liabilities, including U.S. dollar-denominated borrowings. |
TABLE OF CONTENTS
• | Market awareness and acceptance of our products are critical to our commercial success. |
• | Our operating results depend on the performance of third-party distributors, in particular Henry Schein, and sales to key customers, including Heartland Dental, LLC (“Heartland”). |
• | Expanding our sales and marketing capabilities is essential to growing revenue. |
• | We rely on third-party manufacturers and suppliers for the supply, manufacture and protection of our products. |
• | The market opportunities for our products may be smaller than we estimate. |
• | We are dependent on our senior management team and other key personnel. |
• | Our industry is subject to rapid technological and scientific change and intense competition, which could render our products obsolete. |
• | Our products are subject to extensive regulatory requirements across the jurisdictions where they are marketed. |
• | Regulatory authorities may disagree with the regulatory classification of our products, which could require us to pursue different regulatory pathways. |
• | Our products may be subject to product recalls in the future. |
• | Our operations are subject to healthcare fraud and abuse, reimbursement, payment transparency and similar healthcare laws and regulations. |
• | If our marketing, labeling or promotional claims are found to be false, misleading, insufficiently substantiated, off-label or inconsistent with applicable regulatory requirements, we could be subject to enforcement action and reputational harm. |
• | Our employees, distributors, agents, contractors, collaborators and other third parties acting on our behalf may engage in misconduct or other improper activities. |
• | If we are unable to obtain, maintain, defend or enforce adequate intellectual property protection, competitors may develop and commercialize products or technologies similar to ours. |
• | We may in the future be involved in lawsuits to defend or enforce our patents and proprietary rights. |
• | We may in the future be subject to claims against us alleging that we are infringing, misappropriating or otherwise violating the intellectual property rights of third parties, the outcome of which would be uncertain and could have a material adverse effect on our business. |
• | If our trademarks and trade names are not adequately protected, we may not be able to build name recognition. |
• | Intellectual property rights do not necessarily address all potential threats. |
• | Our uses of artificial intelligence, machine learning technologies and AI-enabled clinical workflows pose operational, regulatory, legal and reputational risks. |
TABLE OF CONTENTS
• | We have incurred net losses since our inception and expect to continue to incur losses for the foreseeable future. We may never achieve or sustain profitability. |
• | We may need to raise additional capital in the future. |
• | We have substantial indebtedness and may incur additional indebtedness in the future, which could adversely affect our business, financial condition, results of operations and ability to operate our business. |
• | We may be required to recognize impairment charges for our goodwill and other intangible assets. |
• | We may not be able to utilize our loss carryforwards, deferred interest deductions and other tax attributes. |
• | We could be subject to additional tax liabilities due to changes in tax laws, tax audits or our growth, which could affect our profitability and increase our effective tax rate. |
• | The dual class structure of our shares and the existing ownership of Class B voting rights shares by our Founders have the effect of concentrating voting control with our Founders for the foreseeable future, which will limit or preclude your ability to influence corporate matters. |
• | Our dual class structure may depress the trading price of our Class A ordinary shares. |
• | Our Co-Founders and Co-CEOs have incurred, and we expect will continue to incur, substantial indebtedness for which a substantial number of shares of our Company are pledged as collateral. |
• | As a foreign private issuer and “controlled company” within the meaning of the NYSE corporate governance rules, we are permitted to, and we will, rely on exemptions from certain of the NYSE corporate governance standards, including the requirement that a majority of our board of directors consist of independent directors. Our reliance on such exemptions may afford less protection to holders of our Class A ordinary shares. |
• | We are an “emerging growth company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our Class A ordinary shares less attractive to investors. |
• | We are a Swiss corporation. The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions. |
• | U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against us or our executive officers or our board of directors. |
TABLE OF CONTENTS
• | a requirement to have only two years of audited financial statements and related financial disclosure; |
• | an exemption from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”), with respect to our internal control over financial reporting; |
• | reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and |
• | an exemption from the requirements of holding non-binding advisory votes on executive compensation and golden parachute arrangements. |
TABLE OF CONTENTS
• | the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; |
• | the sections of the Exchange Act establishing liability for insiders who profit from trades made in a short period of time; and |
• | the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K upon the occurrence of specified significant events. |
• | the requirement to obtain shareholder approval for certain issuances of securities, including shareholder approval of equity compensation or purchase plans or other equity compensation arrangements. We will follow Swiss law with respect to any requirement to obtain shareholder approval in connection with such issuances; |
• | the requirement that there be regularly scheduled meetings of only the independent directors. There is no similar requirement under Swiss law. As a result, our independent directors may choose to meet in executive session at their discretion; |
• | the requirement to disclose within four business days any determination to grant a waiver of the Code of Conduct (as defined herein) to directors and officers. While we intend to disclose any amendments to our Code of Conduct, or waivers of its requirements, on our website or in public filings under the Exchange Act, Swiss law does not prescribe a specific timeline for such disclosure; and |
• | the quorum requirements applicable to meetings of shareholders. Swiss law does not require such quorum requirements. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Class A ordinary shares to be issued by us in this offering; |
• | Class A ordinary shares to be issued upon the vesting of RSUs in connection with the completion of this offering that were granted to certain of our officers, directors and employees under our existing equity incentive plans, as more fully described under “Management—Equity Incentive Plans”; and |
• | Class A ordinary shares to be issued in connection with the completion of this offering upon the exercise of certain of outstanding options to acquire our Class A ordinary shares. |
• | 1,591,901 Class A ordinary shares issuable upon the vesting of outstanding RSUs; |
• | 2,516,883 Class A ordinary shares issuable upon the exercise of warrants to acquire our Class A ordinary shares at a weighted average exercise price of CHF 0.006 ($0.007); |
• | 1,838,339 Class A ordinary shares and 5,000,000 Class B voting rights shares reserved for issuance under our equity incentive plans, including under our 2026 Plan (as defined herein), as more fully described under “Management—Equity Incentive Plans;” and |
• | 4,498,951 Class A ordinary shares issuable upon settlement of contractual anti-dilution rights with holders of our outstanding Class B preferred shares in connection with this offering, as described below (based on an assumed initial public offering price of $22.50 per Class A ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus). |
• | the adoption and effectiveness of our Amended and Restated Articles of Association; |
• | no purchase of ordinary shares in this offering by our directors, officers or existing shareholders; |
• | no exercise of the underwriters’ over-allotment option; and |
• | an initial public offering price of $22.50 per Class A ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus. |
TABLE OF CONTENTS
For the Six Months Ended June 30, | For the Years Ended December 31, | |||||||||||
2026 | 2025 | 2025 | 2024 | |||||||||
(thousands of $, except for per share amounts) | ||||||||||||
Net revenue | $28,558 | $9,088 | $30,209 | $12,157 | ||||||||
Cost of goods sold | (3,885) | (4,417) | (7,792) | (8,269) | ||||||||
Research and development expense | (7,159) | (2,002) | (4,575) | (2,641) | ||||||||
Selling, general and administrative expense | (35,064) | (26,750) | (59,925) | (32,213) | ||||||||
Loss from operations | $(17,550) | $(24,081) | $(42,084) | $(30,966) | ||||||||
Interest expense | (9,015) | (4,061) | (11,753) | (3,942) | ||||||||
Loss on loans measured at fair value | (1,205) | (1,474) | (1,647) | (412) | ||||||||
Gain on loan conversion | 1,613 | — | — | — | ||||||||
Loss due to change in the fair value of derivative liabilities | (8) | — | — | — | ||||||||
Loss on term loan extinguishment | (1,580) | (1,245) | (1,628) | — | ||||||||
Other income / (expense), net | (412) | (1,169) | 298 | 184 | ||||||||
Loss before income taxes | $(28,157) | $(32,030) | $(56,813) | $(35,135) | ||||||||
Income tax benefit / (expense) | 350 | (26) | 366 | 398 | ||||||||
Net loss | $(27,807) | $(32,057) | $(56,447) | $(34,737) | ||||||||
Net loss attributable to: | ||||||||||||
Owners of vVARDIS Holding AG | (27,807) | (32,057) | (56,494) | (34,737) | ||||||||
Non-controlling interests | — | — | 48 | — | ||||||||
Loss per ordinary share(1) | ||||||||||||
Basic | $(0.70) | $(0.93) | $(1.60) | $(1.11) | ||||||||
Diluted | $(0.70) | $(0.93) | $(1.60) | $(1.11) | ||||||||
Pro forma Loss per ordinary share(2) | ||||||||||||
Basic – Class A ordinary shares | $(0.56) | — | $(1.54) | — | ||||||||
Diluted – Class A ordinary shares | $(0.56) | — | $(1.54) | — | ||||||||
Basic – Class B voting rights shares | $(0.06) | — | $(0.15) | — | ||||||||
Diluted – Class B voting rights shares | $(0.06) | — | $(0.15) | — | ||||||||
(1) | See Note 11 to our unaudited interim condensed consolidated financial statements and Note 13 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate basic and diluted net loss per share and the weighted average number of shares used in the computation of the per share amounts. |
(2) | Pro forma loss per share gives effect to (i) the effectiveness of our Amended and Restated Articles of Association, which will result in our outstanding ordinary shares being reclassified into Class A ordinary shares and Class B voting rights shares, and the conversion of our Class A preferred shares and Class B preferred shares into Class A ordinary shares, including the elimination of the change in fair value of the embedded derivative liability related to our Class B preferred shares; (ii) the vesting of RSUs and options granted under the 2024 Plan and the 2025 Plan as of June 30, 2026 that vest upon completion of this offering and the recognition of the related share-based compensation expense, as if such vesting had occurred at the beginning of the respective period, and the issuance of 383,285 Class A ordinary shares upon the settlement of RSUs and the |
TABLE OF CONTENTS
Six Months Ended June 30, 2026 | Year Ended December 31, 2025 | |||||
(thousands of $, except share and per share amounts) | ||||||
Numerator: | ||||||
Net loss attributable to owners of vVARDIS Holding AG | $(27,807) | $(56,494) | ||||
Pro forma adjustments related to: | ||||||
Change in fair value of derivative liabilities | 8 | — | ||||
Share-based compensation expense for awards vesting in connection with the offering | — | (9,287) | ||||
Pro forma net loss attributable to shareholders | $(27,799) | $(65,781) | ||||
Allocated to Class A ordinary shares | (19,734) | (43,554) | ||||
Allocated to Class B voting rights shares | (8,065) | (22,226) | ||||
Denominator: | ||||||
Weighted-average ordinary shares used to compute basic and diluted loss per share | 39,948,137 | 35,345,300 | ||||
Conversion of Class A preferred shares as if converted at the beginning of the period(1) | 6,856,791 | 6,856,791 | ||||
Conversion of Class B preferred shares as if converted at the beginning of the period(1) | 668,437 | — | ||||
Class A ordinary shares issued upon settlement of RSUs and exercise of options in connection with the offering | 383,285 | 383,285 | ||||
Class A ordinary shares issued to Class B preferred holders (anti-dilution rights) | 1,739,926 | — | ||||
Pro forma weighted-average ordinary share equivalents | 49,596,575 | 42,585,376 | ||||
Less: ordinary shares held by our Founders converted into Class B voting rights shares(2) | (14,388,879) | (14,388,879) | ||||
Pro forma weighted-average Class A ordinary shares(3) | 35,207,696 | 28,196,497 | ||||
Pro forma weighted-average Class B voting rights shares (ten for each ordinary share held by our Founders)(4) | 143,888,790 | 143,888,790 | ||||
Pro forma net loss per ordinary share | ||||||
Class A ordinary shares – basic and diluted | $(0.56) | $(1.54) | ||||
Class B voting rights shares – basic and diluted | $(0.06) | $(0.15) | ||||
(1) | Excludes four Class A preferred shares and four Class B preferred shares held in treasury. |
(2) | Immediately prior to the completion of this offering, certain ordinary shares held by our Founders will be converted into ten Class B voting rights shares. Because each Class B voting rights share has one-tenth of the economic participation rights of a Class A ordinary share, the issuance of ten Class B voting rights shares for each ordinary share held by our Founders does not increase our Founders’ aggregate economic participation in earnings or distributions. |
(3) | Denominator used for the computation of the pro forma net loss per ordinary share Class A ordinary shares – basic and diluted. |
(4) | Denominator used for the computation of the pro forma net loss per ordinary share Class B ordinary shares – basic and diluted. |
TABLE OF CONTENTS
As of June 30, 2026 | |||||||||
Actual | Pro forma(1) | Pro forma as adjusted(2)(3) | |||||||
(thousands of $) | |||||||||
Cash and cash equivalents | $28,974 | $29,007 | $195,161 | ||||||
Total assets | 104,803 | 104,836 | 270,990 | ||||||
Total liabilities | 164,408 | 132,999 | 132,999 | ||||||
Total shareholder’s (deficit) equity | (118,502) | (28,163) | 137,991 | ||||||
(1) | Pro forma amounts give effect to (i) the effectiveness of our Amended and Restated Articles of Association, including the implementation of the dual-class share structure, the conversion of our Class A preferred shares and Class B preferred shares into Class A ordinary shares and Class B voting rights shares and the reclassification of the embedded derivative liability related to our Class B preferred shares to additional paid-in capital, (ii) the recognition of share-based compensation expense for RSUs and options granted under the 2024 Plan and the 2025 Plan as of June 30, 2026 that vest in connection with this offering, and the issuance of 383,285 Class A ordinary shares upon the settlement of RSUs and the exercise of options granted under the 2024 Plan and the 2025 Plan as of June 30, 2026 that are settled in shares in connection with this offering, and (iii) the issuance of 4,498,951 Class A ordinary shares at par value to holders of our Class B preferred shares pursuant to their contractual anti-dilution rights, based on the assumed initial public offering price referred to in footnote (2) below, in each case as if such events had occurred on June 30, 2026. Pro forma amounts do not give effect to any RSUs or options granted under our 2026 Plan or granted after June 30, 2026, including 161,661 RSUs to be granted under the 2026 Equity Incentive Plan that vest in connection with this offering. See “Capitalization.” |
(2) | Pro forma as adjusted amounts give effect to the pro forma adjustments described in footnote (1) above and the issuance and sale of 8,333,334 Class A ordinary shares by us in the offering at an assumed initial public offering price of $22.50 per Class A ordinary share, the midpoint of the range set forth on the cover page of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, as set forth under “Use of Proceeds.” See “Use of Proceeds” and “Capitalization.” |
(3) | This as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $22.50 per Class A ordinary share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) each of as adjusted cash and cash equivalents, total assets, and total shareholder’s (deficit) equity by $7.8 million (CHF 6.4 million), assuming that the number of Class A ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 in the number of Class A ordinary shares offered by us would increase (decrease) each of as adjusted cash and cash equivalents, total assets and total shareholder (deficit) equity by $20.9 million (CHF 17.2 million), assuming the assumed initial public offering price of $22.50 per Class A ordinary share remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. |
2024 | 2025 | 2026 | |||||||||||||||||||||||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | |||||||||||||||||||||||
Recurring Buying Practices(1) | 1,084 | 1,709 | 2,343 | 2,876 | 3,702 | 4,734 | 6,427 | 7,221 | 7,615 | 8,461 | 11,158 | ||||||||||||||||||||||
% change (YoY) | N/A | N/A | N/A | N/A | 242% | 177% | 174% | 151% | 106% | 79% | 74% | ||||||||||||||||||||||
(1) | We define Recurring Buying Practices at a measurement date as the number of dental practices in the United States that placed more than one order for our products over the last four months. |
TABLE OF CONTENTS
For the Six Months Ended June 30, | For the Years Ended December 31, | |||||||||||
2026 | 2025 | 2025 | 2024 | |||||||||
(thousands of $) | ||||||||||||
Net loss | (27,807) | (32,057) | (56,447) | (34,737) | ||||||||
Add: | ||||||||||||
Interest expense | 9,015 | 4,061 | 11,753 | 3,942 | ||||||||
Income tax (benefit) / expense | (350) | 26 | (366) | (398) | ||||||||
Depreciation and amortization | 2,293 | 1,815 | 3,958 | 3,895 | ||||||||
Share-based compensation expense | 4,007 | 6,358 | 13,884 | 5,890 | ||||||||
Restructuring and other advisory costs(1) | 605 | — | 725 | 593 | ||||||||
Loss on term loan extinguishment | 1,580 | 1,245 | 1,628 | — | ||||||||
Loss on loans measured at fair value | 1,205 | 1,474 | 1,647 | 412 | ||||||||
Gain on loan conversion | (1,613) | — | — | — | ||||||||
Loss due to change in the fair value of derivative liabilities | 8 | — | — | — | ||||||||
Foreign exchange (gains) / losses(2) | 507 | 962 | (224) | (1,153) | ||||||||
Adjusted EBITDA | (10,550) | (16,116) | (23,442) | (21,556) | ||||||||
(1) | Represents costs incurred in connection with restructuring initiatives, including legal, advisory and employee-related costs, as well as advisory costs related to other strategic activities. |
(2) | Represents foreign exchange gains and losses, recorded within Other income/(expense) line item of consolidated statements of operations, arising from the remeasurement of non-functional currency denominated monetary assets and liabilities, including U.S. dollar-denominated borrowings. |
TABLE OF CONTENTS
TABLE OF CONTENTS
• | our ability to increase awareness and understanding of our products and our Curodont® technology platform among dentists, hygienists, DSOs, patients, payors and other stakeholders; |
• | whether there is adequate utilization of our products based on their effectiveness and perceived advantages over those of our competitors as well as alternative traditional treatments, including fluoride varnish, dental sealants and conventional invasive procedures, which are deeply entrenched, widely reimbursed and often perceived by practitioners and payors as sufficient standards of care; |
• | the performance, tolerability and ease of use of our products relative to those currently on the market; |
• | our ability to develop, commercialize and obtain and maintain regulatory clearance or approval for current and future products; |
• | the clinical effectiveness of our products, including the quality and robustness of clinical evidence supporting their use; |
• | the prices at which we and our distributors offer our products; |
• | the effectiveness of our sales and marketing efforts; |
• | our ability to provide incremental data that show the clinical benefits of our products and solutions and to have such data published in peer-reviewed scientific journals; |
• | our ability to educate dental professionals regarding appropriate patient selection, clinical workflows and the potential benefits of our products and to integrate our products into clinical practice and dental education; |
• | the coverage and reimbursement acceptance of our products and services; |
• | pricing pressure, including from DSOs, seeking to obtain discounts on our products based on the collective bargaining power of the DSO members; |
• | negative publicity regarding our or our competitors’ products; and |
• | the effectiveness of our products relative to those of our competitors. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | We did not design and maintain an effective risk assessment process. This material weakness related to the principles associated with the risk assessment component of the COSO Framework, specifically the principles relating to (i) identifying, assessing, and communicating |
TABLE OF CONTENTS
• | We did not design and maintain an effective control environment, including effective information and communication controls. This material weakness related to our legacy enterprise resource planning (“ERP”) environment, which was not appropriately configured to support an effective system of information technology general controls (“ITGCs”), including controls over logical access, program change management, and system operations. As a result, we did not design and maintain effective controls over the completeness and accuracy of system-generated reports relied upon in the financial reporting process; and |
• | We did not design and maintain effective control activities and monitoring controls, including around key account balances such as net revenues. This material weakness resulted from, and was a consequence of, the material weaknesses described above. Because business process controls relied upon system-generated reports and data that were affected by the absence of effective ITGCs, the related control activities were not designed or operating with sufficient precision. In addition, our monitoring activities did not include timely identification, communication, and remediation of control deficiencies, including separate, ongoing evaluations of the system of internal control. |
• | designed and implemented an updated risk and control framework, including a revised risk and control matrix, intended to address the risk assessment deficiencies described above; |
• | designed and implemented ITGCs within the new ERP system addressing logical access, program change management, system operations and the completeness and accuracy of system-generated reports relied upon in the financial reporting process; |
• | updated and implemented related business process controls and documentation to align with the new ERP environment and to ensure that risks are mitigated at the appropriate level of precision and consistency; and |
• | prepared an initial risk assessment and implemented controls intended to standardize and ensure consistency in our monthly financial close process. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | the federal Anti-Kickback Statute (the “AKS”), which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or providing anything of value, directly or indirectly, overtly or covertly, in cash or in kind, in return for, or to induce, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs; |
• | the federal civil False Claims Act, which prohibits any person from knowingly presenting, or causing to be presented, false or fraudulent claims for payment of federal funds, or knowingly making, or causing to be made, a false record or statement to get a false claim paid; |
• | HIPAA (as defined below) imposes criminal liability for, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits, items or services; |
• | HIPAA and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; and |
• | state law equivalents of the foregoing laws, many of which apply to items or services reimbursed by commercial insurers and other nongovernmental payors. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | we may not have been the first to invent the technology covered by our pending patent applications or issued patents; |
• | we may not be the first to file patent applications directed to our inventions, as patent applications in the United States and most other countries are confidential for a period of time after filing; |
• | our methods and related products and technology may not be patentable; |
• | our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; |
• | any or all of our pending patent applications may not result in issued patents; |
• | third parties may own some or all rights to our intellectual property, and we may not have sufficient rights to such intellectual property to cover and protect our products, methods and technology; |
• | others may independently develop identical, similar or alternative products, methods or technology; |
• | others may design around our patent claims to produce competitive products, methods or technology that fall outside of the scope of our patents; |
• | we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection; |
• | we may not seek or obtain patent protection in countries that may eventually provide us a significant business opportunity; |
• | any patents issued to us may not provide a basis for commercially viable products, methods or technology, may not provide any competitive advantages or may be successfully challenged by third parties; |
TABLE OF CONTENTS
• | a third party may challenge our patents in court and, upon such a challenge, a court may not hold that our patents are valid, enforceable and infringed; |
• | a third party may challenge our patents in various patent offices and, if challenged, we may be compelled to limit the scope of our pending, allowed or granted claims or lose some or all of the pending, allowed or granted claims altogether; |
• | the patents of others could harm our business; and |
• | our competitors could conduct research and development activities in countries where we will not have enforceable patent rights and then use the information learned from such activities to develop competitive products, methods or technology for sale in our major commercial markets. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | others may be able to develop products, methods or technology that are similar to ours but that are not protected by our intellectual property; |
• | we might not have been the first to make the inventions covered by our patents; |
• | we might not have been the first to file patent applications covering certain of our or their inventions; |
• | we may not have rights to inventions, patent applications, patents and other intellectual property that we initially believe we have; |
TABLE OF CONTENTS
• | others, including inventors or developers of our owned patented technologies who may become involved with competitors, may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; |
• | it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents; |
• | it is possible that there are prior public disclosures, or other issues such as incorrect designations of inventorship, that could invalidate our issued patents; |
• | issued patents for which we have rights may not provide us with any competitive advantage and may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; |
• | our competitors might conduct research and development activities in countries where we do not have patent rights or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products, methods and technology in our commercial markets; |
• | we may not develop additional proprietary technologies that are patentable; |
• | the patents or pending or future applications of third parties, if issued, may harm our business; and |
• | we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | research and development activities, including the enhancement of existing products and development of new dental treatment technologies and applications; |
• | sales and marketing activities to expand awareness, adoption and utilization of our products among dentists, DSOs, distributors and other commercial partners; |
• | clinical, scientific and educational initiatives designed to support broader adoption of our products and treatment protocols; |
• | expansion of our operational, manufacturing, quality and regulatory infrastructure; |
• | obtaining and maintaining regulatory clearances, approvals, certifications and reimbursement support; |
• | protecting and expanding our intellectual property portfolio; and |
• | hiring additional personnel. |
TABLE OF CONTENTS
• | fund research and development efforts of our products; |
• | increase our sales and marketing efforts to drive market awareness and adoption of our products and to address competitive developments; |
• | acquire, license or invest in complementary technologies and products; |
• | acquire or invest in complementary businesses or assets; and |
• | finance capital expenditures and general and administrative expenses. |
• | our ability to achieve revenue growth; |
• | our ability to secure any required regulatory clearance or approval for additional products, applications and markets; |
• | our rate of progress in, and cost of the sales and marketing activities associated with, maintaining and expanding the adoption of products; |
• | the cost of expanding our research and development, manufacturing and laboratory operations and product offerings; |
• | the rate of progress in establishing payor coverage and reimbursement arrangements with domestic and international commercial third-party payors and government payors by us with respect to our products; |
• | our rate of progress in, and cost of research and development activities associated with, early research and development efforts; |
• | the effect of competing technological and market developments; |
• | market acceptance and adoption of our products; |
TABLE OF CONTENTS
• | costs related to international expansion; and |
• | the potential cost of, and delays in, product development as a result of regulatory oversight. |
• | requiring us to dedicate a substantial portion of our cash flow from operations to the payment of principal, interest and other amounts payable under our indebtedness, thereby reducing the funds available for working capital, capital expenditures, research and development, commercial activities and other general corporate purposes; |
• | increasing our vulnerability to adverse general economic, industry and competitive conditions, including periods of rising interest rates, inflation, reduced consumer spending or constrained capital markets; |
• | exposing us to interest rate risk to the extent any of our indebtedness bears interest at variable rates; |
• | limiting our flexibility in planning for, or reacting to, changes in our business, industry and market conditions; |
• | restricting our ability to pursue strategic acquisitions, investments, partnerships, joint ventures or other business opportunities; |
• | impairing our ability to obtain additional financing on acceptable terms or at all; |
• | placing us at a competitive disadvantage relative to competitors with less indebtedness or greater access to capital; |
TABLE OF CONTENTS
• | increasing the likelihood of a downgrade, withdrawal or other adverse action with respect to any credit ratings we may obtain in the future, which could increase our borrowing costs, limit our access to capital markets and adversely affect investor confidence; and |
• | increasing the risk that we may be unable to satisfy our obligations under our indebtedness when due. |
TABLE OF CONTENTS
• | adverse changes in macroeconomic conditions, including inflation, rising interest rates, recessionary pressures or constrained capital markets; |
• | deterioration in industry conditions or competitive dynamics; |
• | lower-than-expected revenue growth, profitability or cash flows; |
• | significant declines in the market price of our ordinary shares or sustained decreases in our market capitalization; |
• | changes in the regulatory, reimbursement or legal environment in markets in which we operate; |
• | loss of significant customers, distributors, strategic partners or key personnel; |
• | delays, failures or setbacks relating to product commercialization, regulatory approvals, product development or clinical activities; |
• | changes in our business strategy, operating structure, reporting units or the manner in which assets are utilized; |
• | decisions to divest, dispose of or restructure businesses or operations; |
• | increases in discount rates or reductions in projected long-term growth rates used in valuation models; and |
• | other adverse developments affecting our business, operations or financial performance. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | the failure of financial analysts to cover our Class A ordinary shares after this offering or changes in financial estimates by analysts; |
• | actual or anticipated variations in our operating results; |
• | changes in financial estimates by financial analysts, or any failure by us to meet or exceed any of these estimates, or changes in the recommendations of any financial analysts that elect to follow our Class A ordinary shares or the shares of our competitors; |
• | announcements by us or our competitors of significant contracts or acquisitions; |
• | technological innovations by us or our competitors; |
• | future sales of our shares; and |
• | investor perceptions of us and the industries in which we operate. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | the non-Swiss court had jurisdiction pursuant to the PILA; |
• | the judgment of such non-Swiss court has become final and non-appealable; |
• | the judgment does not contravene Swiss public policy; |
• | the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and |
• | no proceeding involving the same parties and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state, and this decision is recognizable in Switzerland. |
• | in certain cases, allow our board of directors to place Class A ordinary shares and/or Class B voting right shares in an amount equivalent to 50% of the expected outstanding share capital after completion of this offering, and rights to acquire additional Class A ordinary shares in an amount equivalent to 30% of the expected outstanding share capital after completion of this offering (i.e., 80% in the aggregate) with affiliates or third parties, without existing shareholders having statutory pre-emptive rights in relation to this share placement; |
• | provide for a dual class share structure with Class B voting rights shares that have ten times the voting power of Class A ordinary shares on a capital-invested basis, which are controlled by our Founders; |
• | establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by shareholders at shareholder meetings; and |
TABLE OF CONTENTS
• | require two-thirds of the votes represented and the majority of the par value of shares represented at a shareholder meeting for amending or repealing certain protective provisions, including the removal of any member of the board of directors or of its (Co-)Chair before the end of his or her term of office. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | on an actual basis; |
• | on a pro forma basis to give effect to (i) the effectiveness of our Amended and Restated Articles of Association, including the implementation of the dual-class share structure, pursuant to which all of our issued ordinary shares, Class A preferred shares and Class B preferred shares will be converted into 28,382,926 Class A ordinary shares and 143,888,790 Class B voting rights shares, and the reclassification of the embedded derivative liability related to our Class B preferred shares to additional paid-in capital, (ii) the increase to accumulated deficit related to the recognition of $9.3 million of incremental share-based compensation expense related to 268,139 RSUs and 486,552 options granted under the 2024 Plan and the 2025 Plan as of June 30, 2026 that will vest in connection with this offering, and the issuance of 383,285 Class A ordinary shares upon the settlement of RSUs and the exercise of options granted under the 2024 Plan and the 2025 Plan as of June 30, 2026 that are settled in shares in connection with this offering, and (iii) the issuance of 4,498,951 Class A ordinary shares to holders of our Class B preferred shares at par value pursuant to their contractual anti-dilution rights, based on an assumed initial public offering price of $22.50 per Class A ordinary share, the midpoint of the price range set forth on the cover page of this prospectus; and |
• | on a pro forma as adjusted basis to give effect to (i) the pro forma adjustments described immediately above and (ii) our sale of the Class A ordinary shares in the offering and the receipt of approximately $166.2 million in estimated net proceeds, assuming an offering price of $22.50 per share (the midpoint of the range set forth on the cover of this prospectus), after deduction of the underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering, and the use of proceeds therefrom. |
As of June 30, 2026 | |||||||||
Actual | Pro Forma | Pro Forma as adjusted | |||||||
(thousands of $, except for share counts) | |||||||||
Cash and cash equivalents | 28,974 | 29,007 | 195,161 | ||||||
Derivative liabilities, non-current | 31,409 | — | — | ||||||
Total loans | 84,207 | 84,207 | 84,207 | ||||||
Mezzanine equity: | |||||||||
Redeemable Series A convertible preferred shares, CHF 0.006 par value: 6,856,795 shares issued and outstanding (actual); no shares issued and no shares outstanding (pro forma) | 44,472 | — | — | ||||||
Redeemable Series B convertible preferred shares, CHF 0.006 par value: 1,728,390 shares issued and outstanding (actual); no shares issued and outstanding (pro forma)(1) | 14,425 | — | — | ||||||
Total Mezzanine equity | 58,897 | — | — | ||||||
TABLE OF CONTENTS
As of June 30, 2026 | |||||||||
Actual | Pro Forma | Pro Forma as adjusted | |||||||
Shareholders’ deficit: | |||||||||
Ordinary Shares, CHF 0.006 par value: 34,186,620 shares issued and outstanding (actual); no shares issued and outstanding (pro forma and pro forma as adjusted) | 227 | — | — | ||||||
Class A ordinary shares, CHF 0.006 par value: no shares issued and outstanding (actual); 33,265,162 shares issued and outstanding (pro forma); 41,543,030 shares issued and outstanding (pro forma as adjusted)(2) | — | 224 | 285 | ||||||
Class B voting rights shares, CHF 0.0006 par value: no shares issued and outstanding (actual); 143,888,790 shares issued and outstanding (pro forma); 143,888,790 shares issued and outstanding (pro forma as adjusted) | — | 96 | 96 | ||||||
Additional paid-in capital | 140,379 | 239,912 | 406,005 | ||||||
Accumulated deficit | (256,322) | (265,609) | (265,609) | ||||||
Accumulated other comprehensive loss | (1,576) | (1,576) | (1,576) | ||||||
Total shareholders’ deficit attributable to owners of vVARDIS Holding AG | (117,292) | (26,953) | 139,201 | ||||||
Non-controlling interest | (1,210) | (1,210) | (1,210) | ||||||
Total shareholders’ deficit | (118,502) | (28,163) | 137,991 | ||||||
Total capitalization | 56,011 | 56,044 | 222,198 | ||||||
(1) | The number of Class A ordinary shares issuable to holders of Class B preferred shares in connection with this offering is subject to contractual anti-dilution rights that depend on the initial public offering price per share in this offering. As a result, holders of our Class B preferred shares will have the right to subscribe for additional Class A ordinary shares for a purchase price equal to their par value. Based on an assumed initial public offering price of $22.50 per Class A ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, holders of our Class B preferred shares will have the right to subscribe for 4,498,951 additional Class A ordinary shares. Based on an assumed initial public offering price of $21.00 per Class A ordinary share, the low end of the price range, holders of our Class B preferred shares would have the right to subscribe for 4,943,710 additional Class A ordinary shares, and based on an assumed initial public offering price of $24.00 per Class A ordinary share, the high end of such price range, holders of our Class B preferred shares would have the right to subscribe for 4,109,781 additional Class A ordinary shares. The pro forma and pro forma as adjusted information set forth in the table above gives effect to the issuance of such additional Class A ordinary shares as of June 30, 2026, which increases each of cash and cash equivalents, share capital and total capitalization by $33 thousand, representing the aggregate par value paid for such shares. |
(2) | As of June 30, 2026, referred to as “ordinary shares.” Following the effectiveness of our Amended and Restated Articles of Association, referred to as “Class A ordinary shares.” |
• | of our 34,186,620 ordinary shares, 6,856,795 Class A preferred shares and 1,728,390 Class B preferred shares issued as of June 30, 2026 are converted at a one-to-one ratio into an aggregate of 42,771,805 Class A ordinary shares. Upon the Conversion, the carrying value of our Class A preferred shares and Class B preferred shares of $58.9 million will be reclassified from mezzanine equity to (i) $57 thousand of share capital, representing the aggregate nominal value of the Class A ordinary shares issued upon conversion of our Class A preferred shares and Class B preferred shares, and (ii) $58.8 million of additional paid-in capital, representing the difference between the carrying value and the nominal value of such preferred shares, within shareholders’ deficit, and the carrying value of the embedded derivative liability related to our Class B preferred shares of $31.4 million will be reclassified from liabilities to additional paid-in capital. As a result, share capital increases from $227 thousand to $284 thousand and additional paid-in capital increases from $140.4 million to $230.6 million; |
TABLE OF CONTENTS
• | of these,14,388,879 Class A ordinary shares held by our Founders are converted into 143,888,790 Class B voting rights shares at a ratio of ten Class B voting rights shares for each Class A ordinary share, resulting in 28,382,926 Class A ordinary shares and 143,888,790 Class B voting rights shares upon the Conversion. Pro forma share capital of $284,000 is allocated (i) $188 thousand to our Class A ordinary shares and (ii) $96 thousand to our Class B voting rights shares. As ten Class B voting rights shares have the same aggregate nominal value as one Class A ordinary share, the conversion of Class A ordinary shares held by our Founders into Class B voting rights shares does not change total share capital or additional paid-in capital; |
• | the recognition of $9.3 million of share-based compensation expense for 268,139 RSUs and 486,552 options granted under the 2024 Plan and the 2025 Plan as of June 30, 2026 that vest in connection with this offering, which increases accumulated deficit with a corresponding increase in additional paid-in capital, and the issuance of 383,285 Class A ordinary shares upon the settlement of RSUs and the exercise of options granted under the 2024 Plan and the 2025 Plan as of June 30, 2026 that are settled in shares in connection with this offering, recorded as $3 thousand of share capital; and |
• | the issuance of 4,498,951 Class A ordinary shares to holders of our Class B preferred shares pursuant to their contractual anti-dilution rights, based on an assumed initial public offering price of $22.50 per Class A ordinary share, the midpoint of the price range set forth on the cover page of this prospectus, for a subscription price equal to their aggregate par value of $33 thousand, which increases cash and cash equivalents and share capital by the same amount (see footnote (1) above). |
TABLE OF CONTENTS
• | the issuance and sale by us of 8,333,334 Class A ordinary shares in this offering at an assumed initial public offering price of $22.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, for estimated net proceeds of $166.2 million, after deducting underwriting discounts and commissions, the financial advisory fee and estimated offering expenses. The estimated net proceeds are recorded as (i) $61 thousand of share capital, representing the aggregate nominal value of the Class A ordinary shares issued in this offering, and (ii) $166.1 million of additional paid-in capital, representing the difference between the estimated net proceeds and such nominal value. Cash and cash equivalents increase by $166.2 million, equal to the estimated net proceeds. |
TABLE OF CONTENTS
TABLE OF CONTENTS
Assumed initial public offering price per Class A ordinary share | $22.50 | |||||
Historical net tangible book value per ordinary share at June 30, 2026 | $(4.67) | |||||
Increase in net tangible book value per Class A ordinary share attributable to the pro forma adjustments described above | $3.21 | |||||
Pro forma net tangible book value per Class A ordinary share after giving effect to the pro forma adjustments described above | $(1.45) | |||||
Increase in pro forma net tangible book value per Class A ordinary share attributable to investors in this offering | $3.19 | |||||
Pro forma as adjusted net tangible book value per Class A ordinary share after giving effect to the pro forma adjustments described above and this offering | $1.73 | |||||
Dilution per Class A ordinary share to investors | $20.77 | |||||
TABLE OF CONTENTS
Shares Purchased | Total Consideration | Average Price Per Share | |||||||||||||
Number | Percent | Amount | Percent | ||||||||||||
(in $ millions) | (in $) | ||||||||||||||
Existing shareholders | 47,598,575 | 85.1% | $198.0 | 51.4% | $4.16 | ||||||||||
Investors in this offering | 8,333,334 | 14.9% | $187.5 | 48.6% | $22.50 | ||||||||||
Total | 55,931,909 | 100.0% | $385.5 | 100.0% | $6.89 | ||||||||||
TABLE OF CONTENTS
¹ | Liu J, et al. “Global, regional, and national burden of untreated dental caries from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.” Int J Epidemiol. 2022;51(4):1291–1303. |
2 | This figure represents the total estimated number of early-stage cavities across the entire U.S. population, including those that we estimate to be undiagnosed among the approximately 35 to 37% of the population that does not currently visit a dentist. |
TABLE OF CONTENTS
TABLE OF CONTENTS
![]() | ![]() | ||
As innovators and self-made serial entrepreneurs, creating new healthcare categories grounded in science. | As visionaries, helping shape global health policy and making an impact on people’s lives. | ||
2020-today: Co-Founders and Co-CEOs of vVARDIS, a healthcare platform spanning clinical care, scientific research, education, and innovation | 2025: Medicaid conference | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
2024 | 2025 | 2026 | |||||||||||||||||||||||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | |||||||||||||||||||||||
Recurring Buying Practices | 1,084 | 1,709 | 2,343 | 2,876 | 3,702 | 4,734 | 6,427 | 7,221 | 7,615 | 8,461 | 11,158 | ||||||||||||||||||||||
% change (YoY) | N/A | N/A | N/A | N/A | 242% | 177% | 174% | 151% | 106% | 79% | 74% | ||||||||||||||||||||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||||||||
2026 | 2025 | Change | % Change | |||||||||
(thousands of $, except percentages) | ||||||||||||
Net revenue | 28,558 | 9,088 | 19,470 | 214.2% | ||||||||
Cost of goods sold | (3,885) | (4,417) | 532 | 12.0% | ||||||||
Research and development expense | (7,159) | (2,002) | (5,157) | 257.6% | ||||||||
Selling, general and administrative expenses | (35,064) | (26,750) | (8,314) | 31.1% | ||||||||
Loss from operations | (17,550) | (24,081) | 6,531 | 27.1% | ||||||||
Interest expense | (9,015) | (4,061) | (4,954) | 122.0% | ||||||||
Loss on loans measured at fair value | (1,205) | (1,474) | 269 | 18.2% | ||||||||
Gain on loan conversion | 1,613 | — | 1,613 | NM | ||||||||
Loss due to change in the fair value of derivative liabilities | (8) | — | (8) | NM | ||||||||
Loss on term loan extinguishment | (1,580) | (1,245) | (335) | 26.9% | ||||||||
Other income / (expense), net | (412) | (1,169) | 757 | 64.8% | ||||||||
Loss before income taxes | (28,157) | (32,030) | 3,873 | 12.1% | ||||||||
Income tax benefit / (expense) | 350 | (26) | 376 | NM | ||||||||
Net loss | (27,807) | (32,057) | 4,250 | 13.3% | ||||||||
TABLE OF CONTENTS
TABLE OF CONTENTS
Year ended December 31, | ||||||||||||
2025 | 2024 | Change | % Change | |||||||||
(thousands of $, except percentages) | ||||||||||||
Net revenue | 30,209 | 12,157 | 18,052 | 148.5% | ||||||||
Cost of goods sold | (7,792) | (8,269) | 477 | 5.8% | ||||||||
Research and development expense | (4,575) | (2,641) | (1,934) | 73.2% | ||||||||
Selling, general and administrative expenses | (59,925) | (32,213) | (27,712) | 86.0% | ||||||||
Loss from operations | (42,084) | (30,966) | (11,118) | 35.9% | ||||||||
Interest expense | (11,753) | (3,942) | (7,811) | 198.2% | ||||||||
Loss on loans measured at fair value | (1,647) | (412) | (1,235) | 299.8% | ||||||||
Loss on term loan extinguishment | (1,628) | — | (1,628) | NM | ||||||||
Other income / (expense) | 298 | 184 | 114 | 62.0% | ||||||||
Loss before income taxes | (56,813) | (35,135) | (21,678) | 61.7% | ||||||||
Income tax benefit | 366 | 398 | (32) | (7.9)% | ||||||||
Net loss | (56,447) | (34,737) | (21,710) | 62.5% | ||||||||
TABLE OF CONTENTS
TABLE OF CONTENTS
Six Months Ended June 30, | Year Ended December 31, | |||||||||||
(in $ thousands) | 2026 | 2025 | 2025 | 2024 | ||||||||
Net loss | (27,807) | (32,057) | (56,447) | (34,737) | ||||||||
Add: | ||||||||||||
Interest expense | 9,015 | 4,061 | 11,753 | 3,942 | ||||||||
Income tax (benefit) / expense | (350) | 26 | (366) | (398) | ||||||||
Depreciation and amortization | 2,293 | 1,815 | 3,958 | 3,895 | ||||||||
Share-based compensation expenses | 4,007 | 6,358 | 13,884 | 5,890 | ||||||||
Restructuring and other advisory costs(1) | 605 | — | 725 | 593 | ||||||||
Loss on term loan extinguishment | 1,580 | 1,245 | 1,628 | — | ||||||||
Loss on loans measured at fair value | 1,205 | 1,474 | 1,647 | 412 | ||||||||
Gain on loan conversion | (1,613) | — | — | — | ||||||||
Loss due to change in the fair value of derivative liabilities | 8 | — | — | — | ||||||||
Foreign exchange (gains) / losses(2) | 507 | 962 | (224) | (1,153) | ||||||||
Adjusted EBITDA | (10,550) | (16,116) | (23,442) | (21,556) | ||||||||
(1) | Represents costs incurred in connection with restructuring initiatives, including legal, advisory and employee related costs, as well as advisory costs related to other strategic activities. |
(2) | Represents foreign exchange gains and losses, recorded within Other income/(expense) line item of consolidated statements of operations, arising from the remeasurement of non-functional currency denominated monetary assets and liabilities, including U.S. dollar-denominated borrowings. |
TABLE OF CONTENTS
TABLE OF CONTENTS
Six Months Ended June 30, | Year Ended December 31, | |||||||||||
(in $ thousands) | 2026 | 2025 | 2025 | 2024 | ||||||||
Net cash used in operating activities | (16,317) | (22,755) | (16,333) | (23,797) | ||||||||
Net cash used in investing activities | — | (247) | (2,805) | (325) | ||||||||
Net cash provided by financing activities | 29,924 | 31,975 | 31,978 | 27,134 | ||||||||
TABLE OF CONTENTS
TABLE OF CONTENTS
Payments Due by Period(1) | |||||||||||||||
As of December 31, 2025 | |||||||||||||||
Borrowings | 1,322 | 29,991 | 88,479 | — | 119,792 | ||||||||||
Lease liabilities | 590 | 1,105 | 941 | — | 2,636 | ||||||||||
Total | 1,912 | 31,096 | 89,420 | — | 122,428 | ||||||||||
(1) | The amounts of contractual obligations set forth in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. The table does not include obligations under agreements that we can cancel without a significant penalty. |
Yield | Maturity Date | As of | ||||||||||||||||
June 30, | December 31, | |||||||||||||||||
2026 | 2025 | 2025 | 2024 | |||||||||||||||
(in $ thousands) | ||||||||||||||||||
2026 Convertible Loan 6% - due to related party | 6.000% | December 2026 | — | 318 | 320 | 280 | ||||||||||||
2026 Convertible Loan 4% - due to related party | 4.000% | December 2026 | — | 944 | 1,009 | 852 | ||||||||||||
2027 Convertible Loan | 7.000% | June 2027 | — | 16,951 | 17,236 | 15,412 | ||||||||||||
Shareholder Loan – due to related party(1) | 8.000% | — | — | 58 | 61 | — | ||||||||||||
2029 PIK Loan | 8.000% | March 2029 | — | — | — | 41,287 | ||||||||||||
2026 Term Loan Tranche I(2) | 8.000% | June 2027 | 11,568 | 10,700 | 11,135 | 10,300 | ||||||||||||
2026 Term Loan Tranche II(2) | 8.000% | June 2027 | 5,636 | 5,212 | 5,419 | 5,012 | ||||||||||||
2030 Term Loan Tranche I | variable | February 2030 | 37,485 | 35,542 | 36,300 | — | ||||||||||||
2030 Term Loan Tranche II | variable | February 2030 | 55,125 | 50,000 | 52,179 | — | ||||||||||||
Less: unamortized discounts and issuance costs | (25,607) | (19,908) | (19,059) | (200) | ||||||||||||||
Total | 84,207 | 99,817 | 104,600 | 72,943 | ||||||||||||||
Less: current maturities | (17,204) | (376) | (1,390) | (280) | ||||||||||||||
Total debt, non-current | 67,003 | 99,441 | 103,210 | 72,663 | ||||||||||||||
(1) | Represents loans provided by our Founders. Such amounts constitute related-party indebtedness. |
(2) | In January 2026, the maturity dates of the 2026 Term Loan Tranche I and 2026 Term Loan Tranche II were extended from August 2026 and December 2026, respectively, to June 30, 2027. No other material terms were modified in connection with the extension. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Key assumption | 2025 | ||
Discount rate | 30% | ||
Terminal growth rate | 2% | ||
TABLE OF CONTENTS
Key assumption | December 31, 2025 | ||
Discount rate | 22.22% | ||
Expected timing of qualifying equity financing | Probability-weighted | ||
TABLE OF CONTENTS
• | We did not design and maintain an effective risk assessment process. This material weakness related to the principles associated with the risk assessment component of the COSO Framework, specifically the principles relating to (i) identifying, assessing and communicating appropriate control objectives, (ii) identifying and analyzing risks to achieving those objectives, (iii) considering the potential for fraud and (iv) identifying and assessing changes that could significantly impact the system of internal control; |
• | We did not design and maintain an effective control environment, including effective information and communication controls. This material weakness related to our legacy ERP environment, which was not appropriately configured to support an effective system of ITGCs, including controls over logical access, program change management and system operations. As a result, we did not design and maintain effective controls over the completeness and accuracy of system-generated reports relied upon in the financial reporting process; and |
• | We did not design and maintain effective control activities and monitoring controls. This material weakness resulted from, and was a consequence of, the material weaknesses described above. |
TABLE OF CONTENTS
• | designed and implemented an updated risk and control framework, including a revised risk and control matrix, intended to address the risk assessment deficiencies described above; |
• | designed and implemented ITGCs within the new ERP system addressing logical access, program change management, system operations and the completeness and accuracy of system-generated reports relied upon in the financial reporting process; |
• | updated and implemented related business process controls and documentation to align with the new ERP environment and to ensure that risks are mitigated at the appropriate level of precision and consistency; and |
• | prepared an initial risk assessment and implemented controls intended to standardize and ensure consistency in our monthly financial close process. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Patient-friendly: needle-free, drill-free and pain-free |
• | Non-invasive: natural tooth structure is preserved |
• | Clinically validated: extensive clinical evidence supporting performance and tolerability |
• | Efficient: up to five-minute treatment duration and single visit procedure |
• | Affordable: comparable treatment cost to small, single-surface “drill-and-fill” procedure, with the potential to minimize future costs associated with increasingly invasive procedures |
• | New, billable treatment option: alternative to the current treatment options for early-stage cavities (“watch-and-wait” and “drill-and-fill”) |
• | Efficient: up to five-minute treatment duration and single-visit procedure, reducing “no show” follow-up appointments |
• | Economical: quicker treatment that allows higher revenue per hour of chair time than conventional treatment options |
TABLE OF CONTENTS
• | Simple-to-use technology: can be performed by a hygienist and requires no extensive or specialized training beyond standard clinical competencies |
• | Patient compliance: supports greater patient retention and visit frequency |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS

(1) | Source: Liu J, et al., “Global, regional, and national burden of untreated dental caries from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.” Int J Epidemiol. 2022; 51(4):1291–1303. |
TABLE OF CONTENTS
TABLE OF CONTENTS

TABLE OF CONTENTS


TABLE OF CONTENTS

TABLE OF CONTENTS

TABLE OF CONTENTS

• | A treatment that helps preserve the tooth from the outset. Because Curodont® is entirely non-invasive, clinicians no longer need to adopt a prolonged “watch-and-wait” approach to early-stage cavities or resort to drilling, which removes healthy tooth structure. Instead, treatment can begin immediately at detection without committing the tooth to a cycle of increasingly invasive treatments that historically begin with the first drilling. |
• | A non-invasive experience that addresses dental anxiety and makes patients of all ages more likely to return. By eliminating drilling, needles and anaesthesia, our flagship Curodont® products, which are non-staining and tasteless, offer a fundamentally different patient experience that we believe can meaningfully reduce dental anxiety and encourage existing patients to return for regular check-ups in order to pursue a drill-free life. We believe this superior experience is itself an adoption driver, as patients who might otherwise defer dental care become more willing to seek, accept and return for treatment. Our market research indicates that a meaningful share of patients presented with the benefits of Curodont® would consider switching dentists to get access to our flagship Curodont® products. |
• | A treatment that frees up chair time and benefits the dental practice. Because the procedure typically takes five minutes or less and can be delegated to a dental |
TABLE OF CONTENTS
• | An affordable solution that is economically beneficial for patients in the long-term. While we continue to pursue broader reimbursement coverage from public and private payors, we believe based on our real-world data that many patients are willing to pay for Curodont® out of pocket due to its comparatively low retail price (comparable to a small, single-surface “drill-and-fill” procedure). In addition, the long-term savings of Curodont®s early intervention are significant as drill-and-fill is more likely to result in an irreversible cycle of increasingly expensive follow-on treatments. Curodont® is billed under CDT code D2991 and is currently covered in part by a number of state Medicaid programs and commercial payors. |

TABLE OF CONTENTS
Citation / Journal | Study Description | Study Conclusions | vVardis’ Role and Involvement | ||||||
Godenzi et al., 2023 / Journal of American Dental Association | Authors: D. Godenzi, C. Bommer, M. Heinzel-Gutenbrunner, J. Horst Keeper and K. Peters Institution: School Dental clinic (Schulzahnklinik), Chur, Switzerland Timeframe: From May 2015 to October 2020 Study design: Retrospective cohort analysis Sample size: 405 early-stage lesions in 219 pediatric patients (average age range: 10-19 years) Description: The retrospective cohort analysis assessed, using bite-wing x-rays, the effect of Curodont® Repair on 405 early-stage cavities on proximal surfaces of permanent teeth in 219 patients in a public pediatric practice. The | At the last available follow-up, no progression (reduction of or no change in severity) was seen in 93% of the treated lesions. Regression occurred in 37-40% of the lesions, with the rate of regression being similar regardless of its initial depth of the lesions. In lesions with a long term follow-up (>2 years), over 90% of the lesions did not cavitate. No serious adverse events were reported. | Authors included Claudine Bommer, a former employee of vVARDIS, and Jeremy Horst Keeper, who was director of clinical innovation at CareQuest Innovation Partners (“CareQuest”). CareQuest was party to a collaboration agreement with vVARDIS regarding deployment and access support for our products in the United States. Costs of statistical analysis, ethics committee fee and mailing costs were paid by vVARDIS. | ||||||
TABLE OF CONTENTS
Citation / Journal | Study Description | Study Conclusions | vVardis’ Role and Involvement | ||||||
lesions were treated with Curodont® Repair followed by once-per-week application of one tube of Curodont® Protect. Changes in stage of cavitation and restoration were assessed over follow-ups ranging between 0.4 and 5.5 years. Results were measured by radiographic assessment of lesion progression, regression and cavitation status using standardized bite-wing x-rays. | |||||||||
Bröseler et al., 2020 / Clinical Oral Investigations | Authors: F. Bröseler, C. Tietmann, C. Bommer, T. Drechsel, M. Heinzel-Gutenbrunner and S. Jepsen Institution: Dental practice in Aachen, Germany Timeframe: From October 2012 to October 2015 Study design: Randomized, controlled double-blinded split-mouth clinical trial Sample size: 88 lesions in 36 patients (average age range: 15-27 years) Description: The clinical trial compared the efficacy of Curodont® Repair to FV in the treatment of early-stage lesions on buccal surfaces of permanent teeth (“White Spot Lesions”). Subjects presenting at least two clinically affected teeth were treated at day 0 and day 90 with Curodont® | HLM analysis showed a significant difference between Curodont® Repair and FV at all follow-up visits, indicating a statistically significant decrease in sizes of lesions treated with Curodont® Repair and stabilization of control lesions (p = 0.001). More rapid and greater decrease in VAS scores was observed in the test group than in the control group, indicating cavity regression in the test group and a tendency of arrest with slight trend toward remineralization in the control group. Additionally, the second application of Curodont® Repair was found to provide no significant benefit, as the cavity regression primarily occurred in the first three months. The authors concluded that Curodont® Repair is the first cavity treatment approach aiming to regenerate decayed enamel by initiating the | Credentis AG served as the primary sponsor of the study, providing monetary support and participating in the study’s plan and design. Authors Frank Bröseler, Christina Tietmann and Monika Heinzel-Gutenbrunner received compensation from Credentis AG for the work performed within the clinical study in line with standard industry practice. Claudine Bommer was an employee of Credentis AG at the time of the study. | ||||||
TABLE OF CONTENTS
Citation / Journal | Study Description | Study Conclusions | vVardis’ Role and Involvement | ||||||
Repair or FV (for the control group). At day 180, FV was applied on all study lesions. Cavity assessment was done with standardized photographs at days 0, 30, 90, 180 and 360 and blindly morphometrically assessed followed by hierarchical linear modelling (“HLM”) to compare the decrease in size between test and control groups. The visual analog scale (“VAS”) and Global Impression of Change Questionnaire were used as clinical assessments. | formation of de novo hydroxyapatite in the depth of early cavities, adding a new advanced therapy option for cavities. Adverse events were not monitored as a study endpoint in this study. | ||||||||
Alkilzy et al., 2018 / Journal of Dental Research | Authors: M. Alkilzy, A. Tarabaih, R.M. Santamaria and C.H. Splieth Institution: University of Greifswald, Germany Timeframe: From February 2013 to April 2014 Study design: Randomized controlled clinical single-blinded trial Sample size: 70 patients (average age range: 7-13 years) Description: The clinical study investigated the safety and clinical efficacy of Curodont® Repair for treatment of early-stage cavities on occlusal surfaces of erupting permanent molars. Subjects were randomized to receive either Curodont® Repair and FV | Compared with FV, Curodont® Repair and FV showed statistically significant improvement in all outcomes at three and six months. The laser fluorescence readings (p = 0.015) and visual analog scale scores (p < 0.0001) were significantly lower for Curodont® Repair and FV, showed regression in the ICDAS index (p = 0.018) and inactivation of lesions (80% with the test group and 34% in the control group; p < 0.0001). No adverse events occurred. Statistical significance was demonstrated across all primary and secondary endpoints. The authors concluded that the biometric approach facilitated by Curodont® Repair and FV is a simple, safe and effective non-invasive treatment for early cavities | This work was financially supported in part by Credentis AG. Credentis AG had no role in study design, data collection, data analysis, data interpretation or writing of the report. | ||||||
TABLE OF CONTENTS
Citation / Journal | Study Description | Study Conclusions | vVardis’ Role and Involvement | ||||||
or FV alone. Cavities were assessed at baseline and at three and six months with laser fluorescence (“DiagnoDent”), a visual analog scale, the ICDAS system and Nyvad cavity activity criteria. Intention-to-treat analyses were performed, and safety and clinical feasibility of the treatment approaches were assessed. | that is superior to the presently used gold standard of fluoride alone. This could avoid additional loss of healthy hard tissue during invasive restorative treatments, potentially enabling longer tooth life and thereby lowering long-term health costs. | ||||||||
Shaalan et al., 2024 / Clinical Oral Investigations | Authors: O. Shaalan, K. Fawzy El-Sayed and E. Abouauf Institution: Cairo University, Egypt Timeframe: From October 2021 to June 2022 Study design: Randomized controlled double blind clinical trial Sample size: 58 lesions in 28 patients (average age range: 18-25 years) Description: The clinical trial compared the effect of Curodont® Repair Fluoride Plus to that of FV with calcium phosphate (“FV-CP”) on White Spot Lesions. Cavity assessment was done at one, three and six months using Diagnodent. | Laser fluorescence scores significantly improved in both groups over time (p < 0.05). At three and six months, Curodont® Repair Fluoride Plus demonstrated statistically lower laser fluorescence readings in comparison to FV-CP (p < 0.05). There was 60% less risk for cavities progression for Curodont® Repair Fluoride Plus when compared to FV-CP after six months. At six months, Curodont® Repair Fluoride Plus led to complete reduction in sizes of 65.5% of the treated lesions, while the rest showed reduction to a lower severity grade. FV-CP led to complete reduction in 13.8% of cases, partial reduction in 82.8% of cases while 3.4% showed no change. Statistical significance was demonstrated (p < 0.05). Curodont® Repair Fluoride Plus showed a higher potential of restoring lost minerals in early cavities than FV over a six-month period. Adverse events were not monitored as a | Credentis AG provided no financial or other support for this study. | ||||||
TABLE OF CONTENTS
Citation / Journal | Study Description | Study Conclusions | vVardis’ Role and Involvement | ||||||
study endpoint in this study. | |||||||||
Cowen et al., 2025 / Dental Advisors | Authors: M. Cowen, M. Gilmartin and J.M. Powers Institution: Dental advisor, United States Timeframe: From January 2025 to February 2025 Study design: In vitro study Sample size: Three human enamel samples Description: This study evaluating the effect of one application of Curodont® Repair Fluoride Plus on the average mineral density of artificial early-stage lesions using Micro-CT and Scanning Electron Microscopy. Lesions were measured at two weeks. | Within two weeks, a statistically significant increase in mineral density was seen (p<0.001), with an average increase in mineral density of 14.3%. Increase in mineral density was observed throughout the full depth of the lesion. Using the Scanning Electron Microscopy analysis, crystals seen in depth and near the surface of the lesion appeared fully fused with sound enamel. Adverse events were not monitored as a study endpoint in this study. | This research was financially supported by vVARDIS. vVARDIS also participated in the planning of the study including its design and review of the results. | ||||||
Welk et al., 2020 / Scientific Reports | Authors: A. Welk, A. Ratzmann, M. Reich, K.F. Krey and Ch. Schwahn Institution: University of Greifswald, Germany Timeframe: From September 2013 to January 2019 Study design: Randomized controlled split-mouth clinical trial Sample size: 23 patients (average age: 15.4 years) Description: The clinical | On the impedance measurements, significantly greater cavity regression was seen at all follow-up visits for the test group, than for the control group (p<0.001). At day 180, the cavities had regressed into the very outer enamel. On morphometric assessment, test group lesion sizes reduced significantly (p=0.004) more than that of those in the control group, at the end of six months (with responses adjusted for baseline values). | Credentis AG provided Curodont® Repair for use in the study. | ||||||
TABLE OF CONTENTS
Citation / Journal | Study Description | Study Conclusions | vVardis’ Role and Involvement | ||||||
trial aimed to evaluate the effect of Curodont® Repair for the treatment of post-orthodontic early cavities on White Spot Lesions in patients with at least two affected teeth. The test teeth were treated with Curodont® Repair on day 0 while the control teeth received fluoride prophylaxis only. All teeth received fluoride prophylaxis at days 45, 90, and 180. The primary endpoint was the impedance measurement to assess cavities regression and progression. The secondary endpoint was the morphometric measurement of White Spot Lesions using a semi-automated approach to determine the White Spot Lesions size in mm2. | The authors concluded that the treatment of early cavities with Curodont® Repair leads to superior regression of the subsurface lesions compared with the control teeth. Statistical significance was demonstrated. Adverse events were not monitored as a study endpoint in this study. | ||||||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Lawful basis for processing. Personal data may only be processed where a recognized legal basis applies, such as the data subject’s consent, the performance of a contract, compliance with a legal obligation or the legitimate interests of the controller, provided such interests are not overridden by the data subject’s rights. |
• | Transparency and information rights. Controllers must provide clear, accessible information to data subjects about how their personal data is collected, used, shared and retained, including the identity of the controller, the purposes and legal bases of processing and the data subject’s rights. |
TABLE OF CONTENTS
• | Data subject rights. Individuals have various rights under the GDPR, including the right to access their personal data, to request rectification or erasure, to restrict or object to certain processing, and to receive their data in a portable format. Controllers must respond to such requests within prescribed timeframes. |
• | Data minimization and purpose limitation. Personal data must be relevant and limited to what is necessary for the specified legitimate purposes for which it is processed and may not be used in a manner incompatible with those purposes. |
• | Storage limitation. Personal data may not be retained for longer than is necessary for the purposes for which it is processed. |
• | Security. Controllers and processors must implement appropriate technical and organizational measures to ensure a level of security appropriate to the risk of processing, including measures to protect against unauthorized or unlawful processing, accidental loss, destruction or damage. |
• | Breach notification. In the event of a personal data breach, controllers must notify the relevant supervisory authority without undue delay and, in certain cases, must also notify affected data subjects. |
• | Data transfers. Transfers of personal data outside the EEA are permitted only where an adequate level of protection is ensured, including through the use of standard contractual clauses approved by the European Commission, adequacy determinations, binding corporate rules or other recognized transfer mechanisms. |
• | Health data. The GDPR imposes heightened obligations on the processing of special categories of personal data, including health data, which may only be processed where an explicit legal basis and at least one additional condition under Article 9 of the GDPR applies. |
• | Data Protection Officers and impact assessments. Certain controllers and processors are required to designate a data protection officer and to conduct data protection impact assessments for processing activities that are likely to result in a high risk to the rights and freedoms of individuals. |
TABLE OF CONTENTS
Location | Primary Function | Approximate Size | ||||
Zug, Switzerland | Office | 555.5 m2 | ||||
Schlieren, Switzerland | Laboratory | 113.2 m2 | ||||
TABLE OF CONTENTS
TABLE OF CONTENTS
Name | Position | Age | ||||
Haley Abivardi | Co-Chief Executive Officer, Co-Founder and Co-Chair | 57 | ||||
Goly Abivardi | Co-Chief Executive Officer, Co-Founder and Co-Chair | 53 | ||||
Thomas Rondot | Chief Financial Officer and Chief People Officer | 53 | ||||
Juergen Stark | Director | 59 | ||||
Clifford zur Nieden | Director | 59 | ||||
Elizabeth Coddington | Director Nominee | 49 | ||||
Steve Swift | Director Nominee | 65 | ||||
Frank Williams | Director Nominee | 57 | ||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | exemption from the requirement that a majority of the board of directors be composed of independent directors and that there be regularly scheduled meetings with only the independent directors present. Swiss law does not have such a requirement; |
• | exemption from the requirements that the compensation committee and the nomination and corporate governance committee be composed of independent directors. Swiss law does not have such requirements; |
• | exemption from quorum requirements applicable to meetings of shareholders. Swiss law does not require such quorum requirements; |
TABLE OF CONTENTS
• | exemption from the requirement that independent directors meet at regularly scheduled executive sessions. Swiss law does not have such a requirement; |
• | exemption from the requirement that listed companies adopt and disclose corporate governance guidelines that cover certain minimum specified subjects related to director qualifications and responsibilities. Swiss law does not require the adoption or disclosure of such guidelines; |
• | exemption from the requirement to disclose within four business days of any determination to grant a waiver of the Code of Conduct to directors and executive officers. Although we will require approval by our board of directors for any such waiver, we may choose not to disclose the waiver in the manner set forth in the NYSE listing standards; and |
• | exemption from the requirement to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans. Our Amended and Restated Articles of Association will provide that our board of directors is authorized, in certain instances, to issue a certain number of Class A ordinary shares without reapproval by our shareholders, as well as Class B voting rights shares to our Founders under employee participation plans. |
• | the majority of our executive officers or directors are U.S. citizens or residents; |
• | more than 50% of our assets are located in the United States; or |
• | our business is administered principally in the United States. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding Class A ordinary shares or Class B voting rights shares; |
• | each of our executive officers and directors and persons nominated to serve in such positions; and |
• | all executive officers, directors and persons nominated to serve in such positions as a group. |
Shares Beneficially Owned Prior to the Offering | Shares Beneficially Owned After the Offering | |||||||||||||||||||||||||||||||||||
Shareholder | Class A Ordinary Shares | % | Class B Voting Shares | % | % of Total Voting Power Prior to the Offering† | % of Total Economic Ownership Prior to the Offering | Class A Ordinary Shares | % | Class B Voting Shares | % | % of Total Voting Power After the Offering† | % of Total Economic Ownership After the Offering | ||||||||||||||||||||||||
Executive Officers: | ||||||||||||||||||||||||||||||||||||
Haley Abivardi(1) | 14,635,193 | 51.7% | 143,888,790 | 100.0% | 92.0% | 67.9% | 14,685,193 | 39.5% | 143,888,790 | 100.0% | 87.6% | 56.4% | ||||||||||||||||||||||||
Goly Abivardi(2) | 14,635,193 | 51.7% | 143,888,790 | 100.0% | 92.0% | 67.9% | 14,685,193 | 39.5% | 143,888,790 | 100.0% | 87.6% | 56.4% | ||||||||||||||||||||||||
Thomas Rondot(3) | 768,013 | 2.6% | — | — | 0.4% | 1.8% | 784,679 | 2.1% | — | — | 0.4% | 1.5% | ||||||||||||||||||||||||
TABLE OF CONTENTS
Shares Beneficially Owned Prior to the Offering | Shares Beneficially Owned After the Offering | |||||||||||||||||||||||||||||||||||
Shareholder | Class A Ordinary Shares | % | Class B Voting Shares | % | % of Total Voting Power Prior to the Offering† | % of Total Economic Ownership Prior to the Offering | Class A Ordinary Shares | % | Class B Voting Shares | % | % of Total Voting Power After the Offering† | % of Total Economic Ownership After the Offering | ||||||||||||||||||||||||
Non-Executive Directors: | ||||||||||||||||||||||||||||||||||||
Clifford zur Nieden | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Juergen Stark(4) | 166,333 | 0.6% | — | — | 0.1% | 0.4% | 166,333 | 0.4% | — | — | 0.1% | 0.3% | ||||||||||||||||||||||||
Director Nominees: | ||||||||||||||||||||||||||||||||||||
Elizabeth Coddington | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Steve Swift | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||
Frank Williams | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||
All directors, director nominees and executive officers as a group (eight persons) | 15,569,539 | 53.6% | 143,888,790 | 100.0% | 92.2% | 69.0% | 15,636,205 | 41.2% | 143,888,790 | 100.0% | 87.7% | 57.4% | ||||||||||||||||||||||||
5% or Greater Shareholders: | ||||||||||||||||||||||||||||||||||||
vVardis Investment Holding AG(5) | 4,275,026 | 15.1% | 143,888,790 | 100.0% | 86.0% | 43.7% | 4,275,026 | 11.5% | 143,888,790 | 100.0% | 81.8% | 36.2% | ||||||||||||||||||||||||
Cerebro Equity GmbH(6) | 2,629,565 | 9.3% | — | — | 1.5% | 6.2% | 2,629,565 | 7.1% | — | — | 1.5% | 5.1% | ||||||||||||||||||||||||
Curo Bidco Limited(7) | 1,827,374 | 6.5% | — | — | 1.1% | 4.3% | 4,782,505 | 11.9% | — | — | 2.6% | 8.8% | ||||||||||||||||||||||||
Heartland Dental, LLC(8) | 2,160,651 | 7.6% | — | — | 1.3% | 5.1% | 3,704,471 | 9.6% | — | — | 2.0% | 7.0% | ||||||||||||||||||||||||
Entities affiliated with OrbiMed Advisors LLC(9) | 2,516,883 | 8.2% | — | — | 1.4% | 5.6% | 2,516,883 | 6.3% | — | — | 1.4% | 4.7% | ||||||||||||||||||||||||
* | Represents beneficial ownership or outstanding total voting power, as applicable, of less than 1%. |
† | Percentage of total voting power represents voting power with respect to all our Class A ordinary shares and Class B voting rights shares, as a single class. Holders of our Class A ordinary shares and holders of Class B voting rights shares are each entitled to one vote per share, irrespective of par value. Since the par value of the Class B voting rights shares is ten times lower than the par value of the Class A ordinary shares, on a capital-invested basis, each Class B voting rights share has ten times the voting power of each Class A ordinary share. See “Description of Share Capital and Articles of Association.” |
(1) | Represents the aggregate number of shares jointly beneficially owned by Dr. Haley Abivardi and Dr. Goly Abivardi. Consists of: (i) 14,635,193 Class A ordinary shares issuable upon conversion of 8,502,386 ordinary shares and 1,857,781 Class A preferred shares, in each case on a one-to-one basis pursuant to the Share Capital Reorganization, 4,275,026 of those Class A ordinary shares are to be issued to vVARDIS Investment Holding AG as described in footnote (5) below and (ii) 143,888,790 Class B voting rights shares that are expected to be issued to vVARDIS Investment Holding AG as described in footnote (5). Dr. Haley Abivardi may be deemed to have voting and dispositive power with respect to the shares held by vVARDIS Investment Holding AG. Dr. Haley Abivardi, Dr. Goly Abivardi and vVARDIS Investment Holding AG have pledged in the aggregate 10,329,426 shares as security for personal loans. See “Risk Factors—Our Co-Founders and Co-CEOs have incurred, and we expect will continue to incur, substantial indebtedness for which shares of our company are pledged as collateral.” Pursuant to their lock-up agreements, Dr. Haley Abivardi, Dr. Goly Abivardi and vVARDIS Investment Holding AG have the ability to pledge additional shares beneficially owned by them in future financing arrangements. In connection with the closing of the offering, Dr. Haley Abivardi and Dr. Goly Abivardi are expected to receive up to an aggregate of 663,230 Class A Ordinary Shares from various shareholders pursuant to an equity distribution and profit participation agreement, although beneficial ownership of such shares is not reflected above. Pursuant to the beneficial ownership rules, the number of shares listed in the table above also includes 50,000 Class A ordinary shares issuable upon settlement of restricted stock units vesting within 60 days of October 30, 2026. |
(2) | Represents the aggregate number of shares jointly beneficially owned by Dr. Haley Abivardi and Dr. Goly Abivardi. Consists of: (i) 14,635,193 Class A ordinary shares issuable upon conversion of 8,502,386 ordinary shares and 1,857,781 Class A preferred shares, in each case on a one-to-one basis pursuant to the Share Capital Reorganization, 4,275,026 of those Class A ordinary shares are to be issued to vVARDIS Investment Holding AG as described in footnote (5) below and (ii) 143,888,790 Class B voting rights shares that are expected to be issued to vVARDIS Investment Holding AG as described in footnote (5). Dr. Goly Abivardi may be deemed to have voting and dispositive power with respect to the shares held by vVARDIS Investment Holding AG. Dr. Haley Abivardi, Dr. Goly Abivardi and vVARDIS Investment Holding AG have pledged in the aggregate 10,329,426 shares as security for personal loans. See “Risk Factors—Our Co-Founders and Co-CEOs have incurred, and we expect will continue to incur, substantial indebtedness for which shares of our company are pledged as collateral.” Pursuant to their lock-up agreements, Dr. Goly Abivardi, Dr. Haley Abivardi and vVARDIS Investment Holding AG have the ability to pledge additional shares beneficially owned by them in future financing arrangements. In connection with the closing of the offering, Dr. Haley Abivardi and Dr. Goly Abivardi are expected to receive up to an aggregate of 663,230 Class A Ordinary Shares from various shareholders pursuant to an equity distribution and profit participation agreement, although beneficial ownership of such shares is not reflected above. Pursuant to the beneficial ownership rules, the number of shares listed in the table above also includes 50,000 Class A ordinary shares issuable upon settlement of restricted stock units vesting within 60 days of October 30, 2026. |
TABLE OF CONTENTS
(3) | Consists of: (i) 16,808 Class A ordinary shares held by Mr. Rondot in his name as of October 30, 2026 and (ii) 34,403 Class A ordinary shares, held jointly by Mr. Rondot and Mr. Rondot’s spouse, Isabelle Grenier, issuable upon conversion of 34,403 Class A preferred shares on a one-to-one basis pursuant to the Share Capital Reorganization. Mr. Rondot may be deemed to share voting and dispositive power with respect to the Class A preferred shares held jointly with Isabelle Grenier. Pursuant to the beneficial ownership rules, the number of shares listed in the table above also includes (i) 716,802 Class A ordinary shares held by Mr. Rondot in his name, issued upon the exercise of options to acquire Class A ordinary shares and (ii) 16,666 Class A ordinary shares issuable upon settlement of restricted stock units vesting within 60 days of October 30, 2026. |
(4) | Consists of 166,333 Class A ordinary shares issuable upon conversion of 166,333 ordinary shares held by the Stark Family Trust as of October 30, 2026. Mr. Stark and Mr. Stark’s spouse, Andrea Stark are the trustees of the Stark Family Trust and, as a result, may be deemed to share voting and dispositive power with respect to the shares held by the Stark Family Trust. |
(5) | Consists of: (i) 4,275,026 Class A ordinary shares remaining following the exchange for Class B voting rights shares described in clause (ii) of 14,388,879 of the 18,663,905 Class A ordinary shares issuable upon conversion of 16,913,905 ordinary shares and 1,750,000 Class A preferred shares, in each case on a one-to-one basis pursuant to the Share Capital Reorganization and (ii) 143,888,790 Class B voting rights shares that are expected to be issued to vVARDIS Investment Holding AG, on a ten-to-one basis pursuant to the Share Capital Reorganization, in exchange for 14,388,879 Class A ordinary shares issued to vVARDIS Investment Holding AG pursuant to clause (i). Dr. Haley Abivardi, Dr. Goly Abivardi and vVARDIS Investment Holding AG have pledged in the aggregate 10,329,426 shares as security for personal loans. Pursuant to their lock-up agreements, Dr. Haley Abivardi, Dr. Goly Abivardi and vVARDIS Investment Holding AG have the ability to pledge additional shares beneficially owned by them in future financing arrangements. Dr. Haley Abivardi and Dr. Goly Abivardi are the controlling shareholders of vVARDIS Investment Holding AG and jointly control such entity. As a result, each of Dr. Haley Abivardi and Dr. Goly Abivardi may be deemed to share voting and dispositive power with respect to the shares held by vVARDIS Investment Holding AG. The address for the entity and persons identified in this footnote is Sihlbruggstrasse 109, 6340 Baar, Switzerland. |
(6) | Consists of 2,629,565 Class A ordinary shares issuable upon conversion of 2,629,565 Class A preferred shares held by Cerebro Equity GmbH as of October 30, 2026, on a one-to-one basis pursuant to the Share Capital Reorganization. Florian Randlkofer holds a majority of the equity interests in Cerebro Equity GmbH and, as a result, may be deemed to have voting and dispositive power with respect to the shares held by Cerebro Equity GmbH. The address for the entity identified in this footnote is Hubertusstrasse 76, 82031 Grünwald, Germany. |
(7) | Consists of: (i) 697,558 Class A ordinary shares (issuable upon conversion of 697,558 ordinary shares held by Curo Bidco Limited, a Cayman Islands exempted company incorporated with limited liability (“Curo”), as of October 30, 2026, (ii) 1,129,816 Class A ordinary shares issuable upon conversion of 1,129,816 Class B preferred shares held by Curo on a one-to-one basis pursuant to the Share Capital Reorganization and (iii) 2,955,131 Class A ordinary shares issuable to Curo in connection with this offering pursuant to the contractual anti-dilution rights of the holders of our Class B preferred shares, based on an assumed initial public offering price of $22.50 per Class A ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus. The Class A ordinary shares described in clause (iii) are reflected only in the number of shares beneficially owned after this offering, and the actual number of such shares will depend on the initial public offering price. See “Prospectus Summary—The Offering.” Apollo Credit Strategies Master Fund Ltd. (“Apollo CS Master Fund”), and Apollo Credit Strategies Absolute Return Aggregator A, L.P. (“Apollo CS ARA”), hold 64% and 36%, respectively, of the outstanding shares of Curo. Apollo ST Fund Management LLC (“Apollo ST Fund Management”), is the investment manager of Apollo CS Master Fund. Apollo ST Operating LP (“Apollo ST Operating”) is the sole member of Apollo ST Fund Management. Apollo ST Capital LLC (“Apollo ST Capital”) is the general partner of Apollo ST Operating. ST Management Holdings, LLC (“ST Management”) is the sole member of Apollo ST Capital. Apollo Credit Strategies Absolute Return Management, L.P. (“Apollo CS AR Management”) is the investment manager of Apollo CS ARA. Apollo Credit Strategies Absolute Return Management GP, LLC (“Apollo CS AR Management GP”) is the general partner of Apollo CS AR Management. Apollo Capital Management, L.P. (“Apollo CM”) is the managing member of ST Management and the sole member of Apollo CS AR Management GP. Apollo Capital Management GP, LLC (“Apollo CM GP”) is the general partner of Apollo CM. Apollo Management Holdings, L.P. (“AMH”) is the manager and sole member of Apollo CM GP. Apollo Management Holdings GP, LLC (“AMH GP”) is the general partner of AMH. Messrs. Scott Kleinman, Marc Rowan and James Zelter are the managers of AMH GP. Each of the entities listed above, other than Apollo CS Master Fund and Apollo CS ARA, and each of Messrs. Rowan, Kleinman and Zelter, disclaims beneficial ownership of any shares held by Curo. The address for each of Apollo ST Fund Management, Apollo ST Operating, Apollo ST Capital, ST Management, Apollo CS AR Management, Apollo CS AR Management GP, Apollo CM, Apollo CM GP, AMH and AMH GP is 9 West 57th Street, 41st Floor, New York, NY 10019. The address for each of Curo, Apollo CS ARA and Apollo CS Master Fund is c/o Walkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. |
(8) | Consists of: (i) 1,562,081 Class A ordinary shares issuable upon conversion of 1,562,081 ordinary shares held by Heartland Dental, LLC (“Heartland”) as of October 30, 2026, (ii) 598,570 Class A ordinary shares (issuable upon conversion of 598,570 Class B preferred shares held by Heartland on a one-to-one basis pursuant to the Share Capital Reorganization and (iii) 1,543,820 Class A ordinary shares issuable to Heartland in connection with this offering pursuant to the contractual anti-dilution rights of the holders of our Class B preferred shares, based on an assumed initial public offering price of $22.50 per Class A ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus. The Class A ordinary shares described in clause (iii) are reflected only in the number of shares beneficially owned after this offering, and the actual number of shares will depend on the initial public offering prices. See “Prospectus Summary—The Offering.” Heartland is a wholly owned subsidiary of Hadrian Intermediate Holdings Inc., which is a wholly owned subsidiary of Heartland Dental Holding Corporation (“HDHC”), which is a controlled subsidiary of Heartland Dental Topco, LLC. Heartland Dental TopCo LLC is majority owned by KKR Hadrian Aggregator L.P., an affiliate of KKR & Co. L.P. Each of the aforementioned entities may be deemed to beneficially own the shares held by Heartland. The board of directors of HDHC approves voting and dispositive decisions with respect to the Class A ordinary shares held by Heartland. The board of directors of HDHC includes Dr. Richard Workman, Patrick Bauer, Eric Niu, Hunter Craig and Alex Ward. Under the so-called “rule of three,” if voting and dispositive decisions regarding an entity’s securities are made by three or more individuals, and a voting and dispositive decision requires the approval of a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity’s securities. Accordingly, no member of the board of directors of HDHC will be deemed to have or |
TABLE OF CONTENTS
(9) | Consists of: (i) 1,785,637 Class A ordinary shares issuable upon the exercise of warrants that are currently exercisable, or exercisable within 60 days of October 30, 2026, held by OrbiMed Royalty & Credit Opportunities IV, LP (“ROS IV Onshore”) and (ii) 731,246 Class A ordinary shares issuable upon the exercise of warrants that are currently exercisable, or exercisable within 60 days of October 30, 2026, held by OrbiMed Royalty & Credit Opportunities IV Offshore, LP (“ROS IV Offshore” and, together with ROS IV Onshore, “ROS IV”). OrbiMed ROF IV LLC (“ROF IV”) is the general partner of each ROS IV entity. OrbiMed Advisors LLC (“OrbiMed Advisors”) is the managing member of ROF IV. By virtue of such relationships, each of ROF IV and OrbiMed Advisors may be deemed to share voting and dispositive power with respect to the Class A ordinary shares issuable upon exercise of the warrants held by ROS IV. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey Hsu, each of whom disclaims beneficial ownership of the Class A ordinary shares issuable upon exercise of the warrants held by ROS IV. The address for the entities and persons identified in this footnote is c/o OrbiMed Advisors LLC, 601 Lexington Avenue, 54th Floor, New York, New York 10022. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | a Founder ceases to hold at least 10% of the number of Class B voting rights shares held by such Founder directly or indirectly immediately following this offering; and |
• | a Founder dies or becomes permanently incapacitated in a manner that causes such Founder to permanently, but not temporarily, be unable to perform such Founder’s function as an executive officer or member of our board of directors. |
TABLE OF CONTENTS
• | conditional share capital (bedingtes Aktienkapital) in the aggregate amount of up to 50% of the share capital for the purpose of issuing shares in connection with, among other things, (i) option and conversion rights granted in connection with warrants and convertible bonds of the Company or one of our subsidiaries or (ii) grants of rights to employees, members of our board of directors or contractors or consultants or to our subsidiaries or other persons providing services to the Company or a subsidiary to subscribe for new shares (conversion or option rights); and/or |
• | in the form of capital range (Kapitalband), which may include also a conditional share capital based on the capital range, empower our board of directors to increase and/or decrease our share capital by up to 50% of the share capital, by issuing or canceling shares, or by increasing or decreasing the par value of shares; such capital range is to be utilized by the board of directors within a period determined by the shareholders but not exceeding five years from the date of the shareholder approval. |
TABLE OF CONTENTS
• | if the issue price of the new shares is determined by reference to the market price; |
• | for raising equity capital in a fast and flexible manner, which would not be possible, or would only be possible with great difficulty or at significantly less favorable conditions, without the exclusion of the subscription rights of existing shareholders; |
• | for the acquisition of companies, parts of companies, participations or of tangible or intangible assets by, or for investment projects of, the Company or any of its group companies, or for the financing or refinancing of any of such transactions through a placement of shares; |
• | for purposes of broadening the shareholder constituency of the Company in certain financial or investor markets, for purposes of the participation of strategic partners, including financial investors, or in connection with the listing of new shares on domestic or foreign stock exchanges; |
• | for purposes of granting an over-allotment option of up to 15% of the shares to be placed or sold in a placement or sale of shares to the respective initial purchaser(s) or underwriter(s); |
• | for the participation of members of the board of directors, members of the executive committee, employees, contractors, consultants, or other persons performing services for the benefit of, the Company or any of its group companies; |
• | for the defense of an actual, threatened or potential takeover bid, that the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended or will not recommend to the shareholders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders; or |
• | for the exchange against shares of the respective other share category. |
TABLE OF CONTENTS
• | adopting and amending the Amended and Restated Articles of Association, including changing the company’s purpose or domicile; |
• | electing and removing of the members of the board of directors, the co-chairs or chair, as applicable, of the board of directors, the members of the nomination and compensation committee, the auditors and the independent proxy; |
• | approving the annual report and the annual statutory and consolidated financial statements and determining the allocation of profits shown on the balance sheet, in particular with regard to dividends; |
• | determining the interim dividend and approving the requisite interim financial statements; |
TABLE OF CONTENTS
• | resolving on the repayment of the statutory capital reserve (gesetzliche Kapitalreserve); |
• | approving the maximum aggregate amount of compensation for the members of the board of directors and the executive committee; |
• | discharging the members of the board of directors and the executive committee from liability with respect to their conduct of business; |
• | resolving on the delisting of the company’s equity securities; |
• | approving the report on non-financial matters, if applicable; and |
• | deciding matters reserved for the general meeting of shareholders by law (including the dissolution of the company with or without liquidation) or the Amended and Restated Articles of Association or, subject to art. 716a CO, submitted by the board of directors. |
• | amending the Company’s corporate purpose; |
• | creating voting right shares; |
• | cancelling or amending the transfer restrictions of shares; |
• | creating conditional share capital or the introduction of a capital range; |
• | increasing share capital out of equity, against contributions in-kind, by set-off against a claim or granting specific benefits; |
• | limiting or withdrawing shareholders’ pre-emptive subscription rights; |
• | changing the currency of the share capital; |
• | introducing a casting vote of the chairperson at the general meeting of shareholders; |
• | introducing a provision in the articles of association concerning the conduct of a general meeting of shareholders abroad; |
• | the removal of any member of the board of directors or of its (co-)chairperson before the end of his or her term of office; |
• | changing the Company’s registered office; |
• | dissolving or liquidating the Company; |
TABLE OF CONTENTS
• | resolving on the consolidation of shares (reverse split); |
• | delisting of the Company’s equity securities; and |
• | introduction of a statutory arbitration clause. |
• | a brief description of the business desired to be brought before the general meeting of shareholders; |
• | the motions regarding the agenda item; |
• | the name and address, as they appear in the share register, of the shareholder(s) proposing such business; |
• | the number of shares which are beneficially owned by such shareholder(s), and the dates upon which the shareholder(s) acquired such shares (including documentary support of such beneficial ownership); and |
• | all other information required under the applicable laws and stock exchange rules. |
TABLE OF CONTENTS
TABLE OF CONTENTS
• | a core part of our business is sold without which it is economically impracticable or unreasonable to continue to operate the remaining business; |
• | our assets, after the divestment, are not invested in accordance with our corporate purpose as set forth in the Amended and Restated Articles of Association; and |
• | the proceeds of the divestment are not earmarked for reinvestment in accordance with our corporate purpose but, instead, are intended for distribution to our shareholders or for financial investments unrelated to our corporate purpose. |
TABLE OF CONTENTS
• | the ultimate direction of the business of the Company and issuing of the relevant directives; |
• | determining the organization of the Company; |
• | formulating accounting procedures, financial controls and financial planning; |
• | nominating and removing persons entrusted with the management and representation of the Company and regulating the power to sign for the Company; |
• | the ultimate supervision of those persons entrusted with the management of the Company, with particular regard to adherence to law, our Amended and Restated Articles of Association and regulations and directives of the Company; |
• | issuing the annual report, the compensation report and, if applicable, the report on non-financial matters and any other reports as required by law; |
• | preparing for the general meeting of shareholders and carrying out its resolutions; |
• | adopting resolutions on the change of the share capital or the currency of the share capital, to the extent that such power is vested in the board of directors, and ascertaining of capital changes, the preparation of the report on the capital increase, and the respective amendments of the articles of association (including deletions); |
• | the non-transferable and inalienable powers and duties of the board of directors pursuant to the Swiss Merger Act; |
• | submitting a petition for debt-restructuring moratorium and informing the court in case of over-indebtedness; and |
• | other powers and duties reserved to the board of directors by law or our Amended and Restated Articles of Association. |
TABLE OF CONTENTS
• | severance payments that are contractually agreed or provided for in the articles of association (compensation due until the termination of a contractual relationship does not qualify as severance payment); |
• | compensation related to a ban on competition that exceeds the average remuneration for the last three financial years, or compensation related to a ban on competition that is not justified on business grounds; |
• | remuneration paid on conditions other than the customary market conditions connected with a previous activity as a corporate body of the company; |
• | joining bonuses that do not compensate for a verifiable financial disadvantage; |
• | advance compensation; |
• | incentive fees / commission for the acquisition or transfer of companies, or parts thereof, by the Company or by companies being directly or indirectly controlled by us; |
TABLE OF CONTENTS
• | loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation not provided for in the Amended and Restated Articles of Association; and |
• | equity-based compensation not provided for in the Amended and Restated Articles of Association. |
• | the maximum aggregate amount of compensation of the board of directors for the term of office until the next annual general meeting of shareholders; |
• | the maximum aggregate amount of compensation of the executive committee (including our executive directors) for the following financial year; and |
• | specific compensation elements for other compensation periods. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
Mergers and similar arrangements | |||
Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock, without a vote by the shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights. | Under Swiss law, with certain exceptions, a merger or a demerger of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the majority of the par value of shares represented at such general meeting of shareholders. A shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant to the Swiss Merger Act (Fusionsgesetz) can file a lawsuit against the surviving company. If the consideration is deemed “inadequate,” such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that if the merger agreement provides only for a compensation payment, at least 90.0% of all members in the transferring legal entity who are entitled to vote shall approve the merger agreement. | ||
Shareholders’ suits | |||
Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party to recover attorneys’ fees incurred in connection with such action. | Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may have a similar effect. A shareholder is entitled to bring suit against directors, officers or liquidators for breach of their duties and claim the payment of the company’s losses or damages to the corporation and, in some cases, to the individual shareholder. Likewise, an appraisal lawsuit won by a shareholder may indirectly compensate all shareholders. In addition, to the extent that U.S. laws and regulations provide a basis for liability and U.S. courts have jurisdiction, a class action may be available. | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
Under Swiss law, the winning party is generally entitled to recover a limited amount of attorneys’ fees incurred in connection with such action. The court has discretion to permit the shareholder who lost the lawsuit to recover attorneys’ fees incurred to the extent that he or she acted in good faith. | |||
Shareholder vote on board and management compensation | |||
Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws. | Pursuant to Swiss law, the general meeting of shareholders has the non-transferable right, amongst others, to vote separately and bindingly on the maximum aggregate amount of compensation of the members of the board of directors, of the executive committee and of the advisory boards (if any). If variable compensation is approved for a future period rather than for a past period, the compensation report is subject to a non-binding / advisory vote of the general meeting of shareholders. | ||
Annual vote on board renewal | |||
Unless directors are elected by written consent in lieu of an annual meeting, directors are elected in an annual meeting of shareholders on a date and at a time designated by or in the manner provided in the bylaws. Re-election is possible. Classified boards are permitted. | The general meeting of shareholders elects the members of the board of directors, the (co-) chairperson(s) of the board of directors and the members of the compensation committee individually and annually for a term of office until the end of the following general meeting of shareholders. Re-election is possible. One year terms of office until the next ordinary general meeting of shareholders are mandatory under Swiss law for listed companies. Classified boards are not permitted. | ||
Indemnification of directors and executive officers and limitation of liability | |||
The Delaware General Corporation Law provides that a certificate of incorporation may contain a provision eliminating or limiting the personal liability of directors and certain officers (“covered officers”) of the corporation for monetary damages for breach of a fiduciary duty as a director, except no provision in the certificate of incorporation may eliminate or limit the liability of a director or covered officer for: • any breach of a director’s or covered officer’s duty of loyalty to the corporation or its shareholders; | Under Swiss corporate law, an indemnification by the corporation of a director or member of the executive committee in relation to potential personal liability is not effective to the extent the director or member of the executive committee intentionally or grossly negligently violated his or her corporate duties towards the corporation. Furthermore, the general meeting of shareholders may discharge (release) the directors and members of the executive committee from liability for their conduct to the extent the respective facts are known to shareholders. Such discharge is effective only with respect to claims of the company and of those shareholders who approved the discharge or who have since acquired their shares | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
• acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; • statutory liability for unlawful payment of dividends or unlawful share purchase or redemption against a director; or • any transaction from which the director or covered officer derived an improper personal benefit; • any claim brought by or on behalf of the corporation (i.e., derivative claims) against a covered officer. | in full knowledge of the discharge. Most violations of corporate law are regarded as violations of duties towards the corporation rather than towards the shareholders. In addition, indemnification of other controlling persons is not permitted under Swiss corporate law, including shareholders of the corporation. | ||
Covered officers eligible for exculpation include any individual who (i) is or was president, chief executive officer, chief operating officer, chief financial officer, chief legal officer, controller, treasurer or chief accounting officer; (ii) is or was a named executive officer identified in the corporation’s SEC filings; or (iii) has by written agreement with the corporation consented to be identified as an officer for purposes of accepting service of process. A Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any proceeding, other than an action by or on behalf of the corporation, because the person is or was a director or officer, against liability incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation; and the director or officer, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. Unless ordered by a court, any foregoing indemnification is subject to a determination that the director or officer has met the applicable standard of conduct: • by a majority vote of the directors who are not parties to the proceeding, even though less than a quorum; • by a committee of directors designated by a majority vote of the eligible directors, even though less than a quorum; | The articles of association of a Swiss corporation may also set forth that the corporation shall indemnify and hold harmless, to the extent permitted by the law, the directors and executive managers out of assets of the corporation against threatened, pending or completed actions. Our Amended and Restated Articles of Association (which will come into force immediately prior to the completion of this offering) provide for such indemnification. Also, a corporation may enter into and pay for directors’ and officers’ liability insurance, which may cover negligent acts as well. | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
• by independent legal counsel in a written opinion if there are no eligible directors, or if the eligible directors so direct; or • by the shareholders. Moreover, a Delaware corporation may not indemnify a director or officer in connection with any proceeding in which the director or officer has been adjudged to be liable to the corporation unless and only to the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances of the case, the director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper. | |||
Directors’ fiduciary duties | |||
A director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: • the duty of care; and • the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, a director must prove the procedural fairness of the transaction, and | The board of directors of a Swiss corporation manages the business of the corporation, unless responsibility for such management has been duly delegated to the executive committee based on organizational rules. However, there are several non-transferable duties of the board of directors: • the overall management of the corporation and the issuing of all necessary directives; • determination of the corporation’s organization; • the organization of the accounting, financial control and financial planning systems as required for management of the corporation; • the appointment and dismissal of persons entrusted with managing and representing the corporation; • the overall supervision of the persons entrusted with managing the corporation, in particular with regard to compliance with the law, articles of association, operational regulations and directives; • the compilation of the annual report, the compensation report, the report on non-financial matters and any other reports required by law, the preparation for the general meeting of the shareholders and implementation of its resolutions; and | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
that the transaction was of fair value to the corporation. | • the filing of an application for a debt restructuring moratorium and notification of the court in the event that the company is over-indebted. The members of the board of directors must perform their duties with all due diligence and safeguard the interests of the corporation in good faith. They must afford the shareholders equal treatment in equal circumstances. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent director would exercise under like circumstances. Members of the board of directors and the executive committee are required to immediately and fully disclose any conflict of interest to the board of directors. The duty of loyalty requires directors to safeguard the interests of the corporation, putting aside their own interests where necessary. Where a risk of conflict exists, the board of directors must take appropriate measures to ensure that the interests of the company are duly protected. The burden of proof for a violation of these duties is with the corporation or with the shareholder bringing a suit against the director. The Swiss Federal Supreme Court has established a doctrine that restricts its review of a business decision if the decision has been taken following proper preparation, on an informed basis and without conflicts of interest. | ||
Shareholder action by written consent | |||
A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent. | Shareholders of a Swiss corporation may exercise their voting rights in a general meeting of shareholders. Shareholders can only act by written consents if no shareholder requests a general meeting of shareholders. The articles of association must allow for (independent) proxies to be present at a general meeting of shareholders. The instruction of such (independent) proxies may occur in writing or electronically. | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
Shareholder proposals | |||
A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings. | At any general meeting of shareholders, any shareholder may put proposals to the meeting if the proposal is part of an agenda item. No resolution may be taken on proposals relating to the agenda items that were not duly notified; exceptions to this are motions to convene an extraordinary general meeting or to carry out a special audit and to appoint an external auditor. Unless the articles of association provide for a lower threshold or for additional shareholders’ rights: • shareholders together representing at least 5% of the share capital or voting rights may demand that a general meeting of shareholders be called for specific agenda items and specific proposals; and • shareholders together representing shares with a par value of at least 0.5% of the share capital or the voting rights may demand that an agenda item including a specific proposal, or a proposal with respect to an existing agenda item, be put on the agenda for a scheduled general meeting of shareholders, provided such request is made with appropriate lead time. | ||
Any shareholder can propose candidates for election as directors or make other proposals within the scope of an agenda item without prior written notice. In addition, any shareholder is entitled, at a general meeting of shareholders and without advance notice, to (i) request information from the board of directors on the affairs of the company (note, however, that the right to obtain such information is limited), (ii) request information from the auditors on the methods and results of their audit, (iii) request that the general meeting of shareholders resolve to convene an extraordinary general meeting or (iv) request that the general meeting of shareholders resolve to appoint an examiner to carry out a special examination (Sonderuntersuchung). | |||
Cumulative voting | |||
Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation’s certificate of incorporation provides for it. | Cumulative voting is not permitted under Swiss corporate law. Pursuant to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate their votes for single | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
candidates. An annual individual election of (i) all members of the board of directors, (ii) the (co-) chairperson(s) of the board of directors, (iii) the members of the compensation committee and (iv) the election of the independent proxy for a term of office of one year (i.e., until the following annual general meeting of shareholders), as well as the vote on the maximum aggregate amount of compensation of the members of the board of directors, of the executive committee and of the members of any advisory board, is mandatory for listed companies. Re-election is permitted. | |||
Removal of directors | |||
A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. | A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by a majority of the voting rights represented at a general meeting of shareholders where a proposal for such removal was properly set on the agenda. The articles of association may require the approval by a supermajority of the voting rights represented at a meeting for the removal of a director. Our Amended and Restated Articles of Association provide for such supermajority. | ||
Transactions with interested shareholders | |||
The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an “interested shareholder” for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation’s outstanding voting shares within the past three years. | No such rule applies to a Swiss corporation. | ||
Dissolution; Winding up | |||
Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. | A dissolution of a Swiss corporation requires the approval by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the majority of the par value of shares represented at such general meeting of shareholders. The articles of association may increase the voting thresholds required for such a resolution. Our Amended and Restated Articles of Association do not provide for such higher threshold. | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
Variation of rights of shares | |||
A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. | The general meeting of shareholders of a Swiss corporation may resolve that preference shares be issued or that existing shares be converted into preference shares with a resolution passed by a majority of the voting rights represented at the general meeting of shareholders. Where a company has issued preference shares, further preference shares conferring preferential rights over the existing preference shares may be issued only with the consent of both a special meeting of the adversely affected holders of the existing preference shares and of a general meeting of all shareholders, unless otherwise provided in the articles of association. Shares with preferential voting rights (such as our Class B voting rights shares) are not regarded as preference shares for these purposes. | ||
Amendment of governing documents | |||
A Delaware corporation’s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. | The articles of association of a Swiss corporation may be amended with a resolution passed by a majority of the voting rights represented at a general meeting of shareholders, unless otherwise provided in the articles of association. There are a number of resolutions, such as an amendment of the stated purpose of the corporation, the introduction of a capital range and conditional capital and the introduction of shares with preferential voting rights, that require the approval by two-thirds of the voting rights and a majority of the par value of the shares represented at such general meeting of shareholders. The articles of association may increase these voting thresholds. | ||
Inspection of books and records | |||
Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose, and to obtain copies of, list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation. | Under Swiss law, any shareholder may request access to the minutes within 30 days following the general meeting. A corporation’s annual report, compensation report and the auditors’ reports must be made available for inspection by shareholders at least 20 calendar days prior to each annual general meeting of shareholders. If the documents are not electronically accessible, (i) any shareholder may request that they be sent to them in good time and (ii) any shareholder may for one year following the general meeting request that they be sent the annual report in the form approved | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
by the general meeting together with the audit reports. At the general meeting, any shareholder is entitled to information from the board of directors on the affairs of the company and information from the external auditors on the methods and results of their audit. Shareholders of a Swiss corporation holding in the aggregate at least 5% of the nominal share capital or voting rights have the right to inspect books and records, subject to the safeguarding of the company’s business secrets and other interests warranting protection. A shareholder is only entitled to receive information to the extent required to exercise his or her rights as a shareholder. The board of directors has to decide on an inspection request within four months after receipt of such request. Denial of the request will need to be justified in writing. If the board of directors denies an inspection request, shareholders may request the order of an inspection by the court within 30 days. A shareholder’s right to inspect the share register is limited to the right to inspect his or her own entry in the share register. | |||
Payment of dividends | |||
The board of directors may approve a dividend without shareholder approval. Subject to any restrictions contained in its certificate of incorporation, the board may declare and pay dividends upon the shares of its capital stock either: • out of its surplus; or • in case there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Shareholder approval is required to authorize capital stock in excess of that provided in the charter. Directors may issue authorized shares without shareholder approval. | Dividend (including interim dividend) payments are subject to the approval of the general meeting of shareholders. The board of directors may propose to shareholders that a dividend shall be paid but cannot itself authorize the distribution. Payments out of a Swiss corporation’s share capital (in other words, the aggregate par value of the corporation’s shares) in the form of dividends are not allowed and may be made only by way of a share capital reduction. Dividends may be paid only from the profits of the previous or current business year or brought forward from previous business years or if the corporation has distributable reserves, each as evidenced by the corporation’s audited stand-alone statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and the articles of association have been deducted. | ||
TABLE OF CONTENTS
DELAWARE CORPORATE LAW | SWISS CORPORATE LAW | ||
Creation and issuance of new shares | |||
All creation of shares requires the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company’s certificate of incorporation. | Any creation of shares requires a shareholders’ resolution. The creation of a capital range or conditional share capital requires at least two-thirds of the voting rights represented at the general meeting of shareholders and a majority of the par value of shares represented at such meeting. The board of directors may issue or cancel shares out of the capital range during a period of up to five years by a maximum amount of 50% (in either direction) of the current share capital. Shares are created and issued out of conditional share capital through the exercise of options or of conversion rights that the board of directors may grant to shareholders, creditors of bonds or similar debt instruments, employees, contractors or consultants, directors of the company or another group company or third parties. | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
• | 1% of the number of our Class A ordinary shares then outstanding, which will equal approximately 372,057 Class A ordinary shares immediately after this offering, assuming no exercise of the underwriters’ over-allotment option to purchase additional Class A ordinary shares; or |
• | the average weekly trading volume of our Class A ordinary shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | certain financial institutions; |
• | dealers or traders in securities who use a mark-to-market method of tax accounting; |
• | persons holding Class A ordinary shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated transaction or persons entering into a constructive sale with respect to the Class A ordinary shares; |
• | persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar; |
• | entities classified as partnerships or S corporations for U.S. federal income tax purposes; |
• | tax-exempt entities, including “individual retirement accounts” or “Roth IRAs”; |
• | real estate investment trusts or regulated investment companies; |
• | persons that own or are deemed to own 10% or more of our shares (by vote or value); or |
• | persons holding Class A ordinary shares in connection with a trade or business conducted outside of the United States. |
• | a citizen or individual resident of the United States; |
• | a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or |
• | an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Underwriters | Number of Shares | ||
Goldman Sachs & Co. LLC | |||
J.P. Morgan Securities LLC | |||
William Blair & Company, L.L.C. | |||
UBS Securities LLC | |||
Deutsche Bank Securities Inc. | |||
Total | |||
Paid by the Company | No Exercise | Full Exercise | ||||
Per Share | $ | $ | ||||
Total | $ | $ | ||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
(i) | to any legal entity which is a “qualified investor” as defined under the Prospectus Regulation; |
(ii) | to fewer than 150 natural or legal persons (other than “qualified investors” as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or |
(iii) | in any other circumstances falling within Article 1(4) of the Prospectus Regulation; |
(i) | at any time to any legal entity which is a qualified investor as defined in paragraph 15 of Schedule 1 to the POATRs; |
(ii) | at any time to fewer than 150 persons (other than qualified investors as defined in paragraph 15 of Schedule 1 to the POATRs) in the United Kingdom subject to obtaining the prior consent of the relevant underwriters nominated by us for any such offer; or |
(iii) | at any time in any other circumstances falling within Part 1 of Schedule 1 to the POATRs. |
TABLE OF CONTENTS
TABLE OF CONTENTS
(i) | to any investor that qualifies as a professional client within the meaning of the FinSA; |
TABLE OF CONTENTS
(ii) | to fewer than 500 investors (other than professional clients within the meaning of the FinSA); |
(iii) | in any other circumstances falling within article 36 of the FinSA; |
TABLE OF CONTENTS
Expenses | Amount | ||
SEC registration fee | $20,000 | ||
FINRA filing fee | 35,000 | ||
NYSE listing fee | 325,000 | ||
Transfer agent’s fees and expenses | 30,000 | ||
Printing expenses | 185,000 | ||
Legal fees and expenses | 4,600,000 | ||
Accounting fees and expenses | 1,600,000 | ||
Miscellaneous fees and expenses | 1,350,000 | ||
Total | $8,145,000 | ||
TABLE OF CONTENTS
• | the non-Swiss court had jurisdiction pursuant to the PILA; |
• | the judgment of such non-Swiss court has become final and non-appealable; |
• | the judgment does not contravene Swiss public policy; |
• | the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and |
• | no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in Switzerland. |
TABLE OF CONTENTS
TABLE OF CONTENTS
Report of Independent Registered Public Accounting Firm | F-2 | ||
Consolidated Balance Sheets | F-3 | ||
Consolidated Statements of Operations | F-4 | ||
Consolidated Statements of Comprehensive Loss | F-5 | ||
Consolidated Statements of Mezzanine Equity and Shareholders’ Equity (Deficit) | F-6 | ||
Consolidated Statements of Cash Flows | F-7 | ||
Notes to Consolidated Financial Statements of vVARDIS Holding AG and Subsidiaries | F-9 | ||
Unaudited Condensed Consolidated Balance Sheets | F-38 | ||
Unaudited Condensed Consolidated Statements of Operations | F-40 | ||
Unaudited Condensed Consolidated Statements of Comprehensive Loss | F-41 | ||
Unaudited Condensed Consolidated Statements of Mezzanine Equity and Shareholders’ Equity (Deficit) | F-42 | ||
Unaudited Condensed Consolidated Statements of Cash Flows | F-44 | ||
Notes to Unaudited Condensed Consolidated Financial Statements of vVARDIS Holding AG and Subsidiaries | F-46 | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
December 31, 2025 | December 31, 2024 | |||||
Assets | ||||||
Cash and cash equivalents | $17,470 | $2,343 | ||||
Accounts receivable, net of allowances of $202 and $176, respectively | 3,042 | 2,037 | ||||
Inventories | 8,616 | 8,334 | ||||
Advances to Suppliers | 2,065 | 47 | ||||
Prepaid expenses | 624 | 289 | ||||
Other current assets | 1,703 | 1,088 | ||||
Total current assets | 33,520 | 14,138 | ||||
Property and equipment, net | 829 | 142 | ||||
Operating lease right-of-use assets | 2,456 | 65 | ||||
Intangible assets, net | 31,823 | 29,748 | ||||
Goodwill | 13,387 | 11,751 | ||||
Deferred tax assets | — | 1 | ||||
Restricted cash | 211 | 62 | ||||
Other non-current assets | 1,002 | — | ||||
Total assets | $83,228 | $55,907 | ||||
Liabilities and shareholders’ (deficit) equity | ||||||
Accounts payable | $6,857 | $4,653 | ||||
Loans, current - due to related party | 1,390 | 280 | ||||
Current operating lease liabilities | 522 | 66 | ||||
Deferred revenue, current | 7,500 | — | ||||
Accrued compensation and benefits | 4,149 | 2,382 | ||||
Accrued operating expenses | 4,482 | 2,566 | ||||
Other current liabilities | 2,373 | 1,026 | ||||
Total current liabilities | 27,273 | 10,972 | ||||
Non-current operating lease liabilities | 1,935 | — | ||||
Deferred revenue, non-current | 7,500 | |||||
Convertible loans, non-current | 17,236 | 16,264 | ||||
Loans, non-current | 85,974 | 56,399 | ||||
Liability for pension benefits | 1,126 | 1,229 | ||||
Deferred tax liabilities | 2,501 | 2,544 | ||||
Total liabilities | 143,545 | 87,408 | ||||
Commitments and contingencies (Note 17) | ||||||
Mezzanine equity:(1) | ||||||
Redeemable Series A convertible preferred shares, CHF 0.006 par value; 6,856,795 shares authorized, issued and outstanding as of December 31, 2025 and 2024, respectively | 44,472 | 44,472 | ||||
Shareholder’s (deficit) equity: | ||||||
Ordinary shares, CHF 0.006 par value; 66,131,140 shares authorized, 31,822,153 and 31,731,320 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 209 | 208 | ||||
Additional paid-in capital | 126,398 | 97,518 | ||||
Accumulated deficit | (228,515) | (172,068) | ||||
Accumulated other comprehensive loss | (1,748) | (603) | ||||
Total shareholders’ deficit attributable to owners of vVARDIS Holding AG | (103,656) | (74,945) | ||||
Non-controlling interests | (1,133) | (1,028) | ||||
Total shareholder’s (deficit) equity | (104,789) | (75,973) | ||||
Total liabilities, mezzanine equity and shareholders’ equity | $83,228 | $55,907 | ||||
(1) | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Net revenue | $30,209 | $12,157 | ||||
Cost of goods sold | (7,792) | (8,269) | ||||
Research and development expense | (4,575) | (2,641) | ||||
Selling, general and administrative expense | (59,925) | (32,213) | ||||
Loss from operations | (42,084) | (30,966) | ||||
Interest expense | (11,753) | (3,942) | ||||
Loss on loans measured at fair value | (1,647) | (412) | ||||
Loss on term loan extinguishment | (1,628) | — | ||||
Other income / (expense) | 298 | 184 | ||||
Loss before income taxes | (56,813) | (35,135) | ||||
Income tax benefit | 366 | 398 | ||||
Net loss | $(56,447) | $(34,737) | ||||
Net loss attributable to: | ||||||
Owners of vVARDIS Holding AG | (56,494) | (34,737) | ||||
Non-controlling interests | 48 | — | ||||
Loss per ordinary share | ||||||
Basic(1) | $(1.60) | $(1.11) | ||||
Diluted(1) | $(1.60) | $(1.11) | ||||
Weighted average shares outstanding | ||||||
Basic and diluted | 35,345,300 | 31,351,517 | ||||
(1) | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Net loss | $(56,447) | $(34,737) | ||||
Other comprehensive (loss)/gain, net of tax: | ||||||
Foreign currency translation adjustments, net of tax, $0 | (1,577) | (1,447) | ||||
Net actuarial gain /(loss) on defined benefit pension plans, net of tax, $0 | 327 | (581) | ||||
Total other comprehensive loss | $(1,250) | $(2,028) | ||||
Comprehensive loss | $(57,697) | $(36,765) | ||||
Comprehensive loss attributable to: | ||||||
Owners of vVARDIS Holding AG | (57,592) | (36,784) | ||||
Non-controlling interests | (105) | 19 | ||||
TABLE OF CONTENTS
Redeemable Series A Convertible Preferred Shares | Ordinary Shares | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive gain/(loss) | Total shareholders’ equity (deficit) | Non- controlling interests | Total equity (deficit) | ||||||||||||||||||||||||||
Shares(1) | Par value | Amount | Shares(1) | Par value | |||||||||||||||||||||||||||||
Balance as of January 01, 2024 | 6,856,795 | $45 | $44,472 | 30,335,222 | $199 | $90,569 | $(137,331) | $1,444 | $(45,118) | $(1,047) | $(46,166) | ||||||||||||||||||||||
Net loss | — | — | — | — | — | — | (34,737) | — | (34,737) | — | (34,737) | ||||||||||||||||||||||
Other comprehensive gain | — | — | — | — | — | — | — | (2,047) | (2,047) | 19 | (2,028) | ||||||||||||||||||||||
Share-based compensation | — | — | — | — | — | 6,948 | — | — | 6,948 | — | 6,948 | ||||||||||||||||||||||
Issuance of ordinary shares | — | — | — | 1,396,098 | 9 | — | — | — | 9 | — | 9 | ||||||||||||||||||||||
Balance as of December 31, 2024 | 6,856,795 | $45 | $44,472 | 31,731,320 | $208 | $97,518 | $(172,068) | $(603) | $(74,945) | $(1,028) | $(75,973) | ||||||||||||||||||||||
Net loss | — | — | — | — | — | — | (56,447) | — | (56,447) | — | (56,447) | ||||||||||||||||||||||
Other comprehensive gain | — | — | — | — | — | — | — | (1,145) | (1,145) | (105) | (1,250) | ||||||||||||||||||||||
Share-based compensation | — | — | — | — | — | 13,879 | — | — | 13,879 | — | 13,879 | ||||||||||||||||||||||
Issuance of warrants | — | — | — | — | — | 15,001 | — | — | 15,001 | — | 15,001 | ||||||||||||||||||||||
Issuance of ordinary shares | — | — | — | 90,833 | 1 | — | — | — | 1 | — | 1 | ||||||||||||||||||||||
Balance as of December 31, 2025 | 6,856,795 | $45 | $44,472 | 31,822,153 | $209 | $126,398 | $(228,515) | $(1,748) | $(103,656) | $(1,133) | $(104,789) | ||||||||||||||||||||||
(1) | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Cash flows from operating activities: | ||||||
Net loss | $(56,447) | $(34,737) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Adjustments to fair value in debt | 1,656 | 476 | ||||
Loss on term loan extinguishment | 1,488 | — | ||||
Depreciation and amortization | 3,956 | 3,895 | ||||
Amortization of debt issuance costs | 1,089 | 48 | ||||
Deferred income taxes | (370) | (415) | ||||
Pension benefits | (256) | 640 | ||||
Non-cash interest expense | 5,988 | 3,626 | ||||
Share-based compensation | 13,672 | 6,957 | ||||
Non-cash lease expense | — | 182 | ||||
Unrealized loss on foreign exchange | (2,782) | (1,535) | ||||
Provision for credit losses | (16) | 69 | ||||
Changes in operating assets and liabilities | ||||||
Decrease (increase) in accounts receivable | (937) | 353 | ||||
Decrease (increase) in inventories | 723 | 909 | ||||
Decrease (increase) in advances to suppliers | (1,908) | 995 | ||||
Decrease (increase) in prepaid expenses | (416) | 306 | ||||
Decrease (increase) in other current assets | (12) | (633) | ||||
Decrease (increase) in other non-current assets | (937) | — | ||||
Increase (decrease) in accounts payable | 88 | (4,183) | ||||
Increase (decrease) in deferred revenue | 15,000 | — | ||||
Increase (decrease) in accrued compensation and benefit | 1,508 | (752) | ||||
Increase (decrease) in accrued operating expenses | 1,610 | (401) | ||||
Increase (decrease) in other current liabilities | 971 | 600 | ||||
Increase (decrease) in operating lease liabilities | (1) | (197) | ||||
Net cash used in operating activities | (16,333) | (23,797) | ||||
Cash flows from investing activities: | ||||||
Acquisition of property and equipment | (760) | (47) | ||||
Acquisition of intangible assets | (2,045) | (278) | ||||
Net cash used in investing activities | (2,805) | (325) | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of loans, current - due to related party | 542 | 10,367 | ||||
Proceeds from issuance of convertible loans | — | 16,338 | ||||
Proceeds from issuance of loans, non-current | 66,453 | 15,000 | ||||
Proceeds from issuance of warrants | 15,715 | — | ||||
Repayment of long-term debt | (48,000) | (2,793) | ||||
Repayment of loans, current - due to related party | (483) | (11,787) | ||||
Debt issuance costs | (2,250) | — | ||||
Proceeds from issuance of share capital | 1 | 9 | ||||
Net cash provided by financing activities | 31,978 | 27,134 | ||||
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | 2,436 | (888) | ||||
Cash, cash equivalents and restricted cash: | ||||||
Net change during the period | 15,276 | 2,124 | ||||
Balance, beginning of period | 2,405 | 281 | ||||
Cash, cash equivalents and restricted cash at end of year | $17,681 | $2,405 | ||||
Supplemental cash flow information: | ||||||
Interest paid | 6,452 | 492 | ||||
Debt issuance costs not yet paid | 1,500 | — | ||||
Right-of-use assets obtained in exchange for operating lease obligations | 2,230 | — | ||||
December 31, 2025 | December 31, 2024 | |||||
Total presented in the Statements of Cash Flows | $17,681 | $2,405 | ||||
Of which in the Balance Sheets: | ||||||
- Cash and cash equivalents | 17,470 | 2,343 | ||||
- Restricted cash | 211 | 62 | ||||
Total | $17,681 | $2,405 | ||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Description | Estimated Useful Life | ||
Office Equipment | 3 years | ||
Laboratory Equipment | 5 years | ||
Description | Estimated Useful Life | ||
Patents | 3-13 years | ||
Trademark | 10 years | ||
Internet Domain | 3 years | ||
Software and website development costs | 5 years | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Level 1 — Quoted prices in active markets for identical assets and liabilities. |
• | Level 2 — Quoted prices in active markets for similar assets and liabilities, or other inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. |
• | Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flows methodologies, and similar techniques that use significant unobservable inputs. |
TABLE OF CONTENTS
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Net revenue | $30,209 | $12,157 | ||||
Cost of goods sold | (7,309) | (7,882) | ||||
Logistical expenses | (483) | (386) | ||||
Research and development expense | (4,575) | (2,641) | ||||
SG&A expenses - people costs* | (37,324) | (18,582) | ||||
SG&A expenses - non-people costs** | (12,015) | (6,698) | ||||
SG&A expenses - restructuring and other advisory costs*** | (725) | (593) | ||||
Marketing expenses | (5,905) | (2,445) | ||||
Depreciation and amortization | (3,958) | (3,895) | ||||
Other financial income / (expense) | 298 | 184 | ||||
Interest expense | (11,753) | (3,942) | ||||
Loss on loans measured at fair value | (1,647) | (412) | ||||
Loss on term loan extinguishment | (1,628) | — | ||||
Income tax benefit | 366 | 398 | ||||
Net loss | $(56,447) | $(34,737) | ||||
* | Related to personnel expenses such as payroll, bonus and other employee benefits |
** | Related to professional fees and services and office related cost (including rent, utilities and other general administrative expenses) |
*** | Represents costs incurred in connection with restructuring initiatives, including legal, advisory and employee-related costs, as well as advisory costs related to other strategic activities |
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Net revenues: | ||||||
United States | $28,737 | $10,938 | ||||
Italy | 354 | 288 | ||||
United Kingdom | 225 | 136 | ||||
Switzerland | 583 | 451 | ||||
Others | 310 | 344 | ||||
Total | $30,209 | $12,157 | ||||
December 31, 2025 | December 31, 2024 | |||||
Accounts receivable, gross | $3,244 | $2,213 | ||||
Less: Allowance for credit losses | (202) | (176) | ||||
Accounts receivable, net | $3,042 | $2,037 | ||||
December 31, 2025 | December 31, 2024 | |||||
Balance, beginning of the period | $176 | $113 | ||||
Expected credit losses | 17 | 144 | ||||
Write-offs | — | (75) | ||||
Foreign exchange effects | 9 | (6) | ||||
Balance, end of the period | $202 | $176 | ||||
TABLE OF CONTENTS
December 31, 2025 | December 31, 2024 | |||||
Raw materials and components | $3,534 | $3,171 | ||||
Work in process | 3,176 | 3,450 | ||||
Finished goods | 2,185 | 5,629 | ||||
Total inventories, gross | $8,895 | $12,250 | ||||
Less: Provision for excess & obsolescence | (279) | (3,916) | ||||
Total inventories, net | $8,616 | $8,334 | ||||
December 31, 2025 | December 31, 2024 | |||||
Laboratory equipment | $803 | $501 | ||||
Other equipment | 188 | — | ||||
Total property and equipment, gross | 992 | 501 | ||||
Less: accumulated depreciation | (163) | (359) | ||||
Total property and equipment, net | $829 | $142 | ||||
TABLE OF CONTENTS
Year Ended December 31, 2024 | ||||||||||||
Weighted Average Remaining Lives | Cost | Accumulated Amortization | Net | |||||||||
Finite-lived Intangible Assets: | ||||||||||||
Trademark | 8 yrs | $7,341 | $(3,019) | $4,322 | ||||||||
Patents | 9 yrs | 47,640 | (22,428) | 25,212 | ||||||||
Internet domain | — | 608 | (608) | — | ||||||||
Software | — | 394 | (180) | 214 | ||||||||
Total intangible assets | $55,983 | $(26,235) | $29,748 | |||||||||
Year Ended December 31, 2025 | ||||||||||||
Weighted Average Remaining Lives | Cost | Accumulated Amortization | Net | |||||||||
Finite-lived Intangible Assets: | ||||||||||||
Trademark | 7 yrs | $8,363 | $(4,275) | $4,088 | ||||||||
Patents | 8 yrs | 54,270 | (28,602) | 25,668 | ||||||||
Software | 5 yrs | 2,268 | (201) | 2,067 | ||||||||
Total intangible assets | $64,901 | $(33,078) | $31,823 | |||||||||
2026 | 4,302 | ||
2027 | 4,302 | ||
2028 | 4,302 | ||
2029 | 4,302 | ||
2030 | 4,219 | ||
December 31, 2025 | December 31, 2024 | |||||
Balance as of beginning of the year | $11,751 | $12,615 | ||||
Foreign currency translation | 1,636 | (864) | ||||
Balance as of the end of the year | $13,387 | $11,751 | ||||
TABLE OF CONTENTS
Level | December 31, 2025 | December 31, 2024 | |||||||
Financial Assets: | |||||||||
Cash and cash equivalents | 1 | 17,470 | 2,343 | ||||||
Restricted cash | 2 | 211 | 62 | ||||||
Accounts receivable | 2 | 3,042 | 2,037 | ||||||
Other current assets | 2 | 1,703 | 1,424 | ||||||
Financial liabilities: | |||||||||
Accounts payable | 2 | 6,859 | 4,651 | ||||||
Loans, non-current | 2 | 85,974 | 56,599 | ||||||
Loans, current - due to related party | 2 | 1,390 | 1,132 | ||||||
Convertible Loans, non-current | 3 | 17,236 | 15,412 | ||||||
Other current liabilities and accrued expenses (Note 11) | 2 | 11,004 | 5,974 | ||||||
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Balance as of January 1 | $15,412 | $— | ||||
Issuances | — | 15,000 | ||||
Change in fair value recognized | 1,824 | 412 | ||||
Balance as of December 31 | $17,236 | $15,412 | ||||
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Operating lease cost | $259 | $186 | ||||
Total lease cost | $259 | $186 | ||||
December 31, 2025 | December 31, 2024 | |||||
Operating leases: | ||||||
Total operating lease ROU assets | $2,456 | $65 | ||||
Non-current portion of operating lease liabilities | 1,935 | — | ||||
Current portion of operating lease liabilities | 522 | 66 | ||||
Total operating lease liabilities | $2,457 | $66 | ||||
December 31, 2025 | December 31, 2024 | |||||
Cash paid for amounts included in the measurement of operating lease liabilities | (389) | (199) | ||||
Weighted average remaining lease term (in months) | 56 | 9 | ||||
Weighted average discount rate (in percent) | 3% | 3% | ||||
2026 | $590 | ||
2027 | 568 | ||
2028 | 537 | ||
2029 | 537 | ||
2030 | 404 | ||
Thereafter | — | ||
Total undiscounted lease payments | 2,635 | ||
Less imputed interest | 178 | ||
Total lease liabilities | $2,457 | ||
TABLE OF CONTENTS
Effective Interest Rates | Maturities | December 31, 2025 | December 31, 2024 | |||||||||
2026 Convertible Loan 6% - due to related party | 6% | Dec – 2026 | $320 | $280 | ||||||||
2026 Convertible Loan 4% - due to related party | 4% | Dec – 2026 | 1,009 | 852 | ||||||||
2027 Convertible Loan | 7% | Jun – 2027 | 17,236 | 15,412 | ||||||||
Shareholder Loan - due to related party | 8% | 61 | — | |||||||||
2029 PIK Loan | 8% | Mar – 2029 | — | 41,287 | ||||||||
2026 Term Loan Tranche I* | 8% | Jun – 2027 | 11,135 | 10,300 | ||||||||
2026 Term Loan Tranche II* | 8% | Jun – 2027 | 5,419 | 5,012 | ||||||||
2030 Term Loan Tranche I | 11% | Feb – 2030 | 36,300 | — | ||||||||
2030 Term Loan Tranche II | 16% | Feb – 2030 | 52,179 | — | ||||||||
Less: unamortized discounts and issuance costs | (19,059) | (200) | ||||||||||
Total loans | $104,600 | $72,943 | ||||||||||
Less: current maturities | (1,390) | (280) | ||||||||||
Total loans, non-current | $103,210 | $72,663 | ||||||||||
* | In accordance with the applicable accounting standards, a current debt obligation should be excluded from current liabilities if the entity has both the intent and ability to refinance the obligation on a long-term basis. Such intent and ability is evidenced by a post-balance-sheet-date issuance of a long-term obligation. As of December 31, 2025, 2026 Term Loan Tranche I and 2026 Term Loan Tranche II had maturities of August 2026 and December 2026, respectively. In January 2026, both maturity dates were extended to June 2027, with no other material modifications to the terms of the agreements. As a result, these obligations are classified as non-current in the accompanying Consolidated Balance Sheets. Refer to Note 19 for additional details. |
TABLE OF CONTENTS
TABLE OF CONTENTS
2026 | 1,322 | ||
2027 | 29,991 | ||
2028 | — | ||
2029 | — | ||
2030 | 88,479 | ||
Thereafter | — | ||
Total | $119,792 | ||
December 31, 2025 | December 31, 2024 | |||||
Accrued compensation and benefits | ||||||
Accrued bonus expense | $3,018 | $2,095 | ||||
Accrued other personnel expenses | 1,131 | 287 | ||||
Total accrued compensation and benefits | $4,149 | $2,382 | ||||
Accrued operating expenses | ||||||
Accrued consulting and other services | $2,455 | $2,566 | ||||
Accrued marketing expenses | 514 | — | ||||
Customer credit balance | 1,513 | — | ||||
Total accrued operating expenses | $4,482 | $2,566 | ||||
Other current liabilities | ||||||
Accrued rebate | $1,358 | $260 | ||||
Accrued inventory purchases | 1,015 | 169 | ||||
Other current liabilities | — | 597 | ||||
Total Other current liabilities | $2,373 | $1,026 | ||||
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Switzerland | $(39,564) | $(26,294) | ||||
Foreign | (17,249) | (8,841) | ||||
$(56,813) | $(35,135) | |||||
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Switzerland | $(4) | $(17) | ||||
Foreign | — | — | ||||
$(4) | $(17) | |||||
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Switzerland | $370 | $415 | ||||
Foreign | — | — | ||||
$370 | $415 | |||||
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Deferred tax benefit (exclusive of the effects of other components below) | $1,677 | $415 | ||||
Adjustments to deferred tax assets and liabilities for enacted changes in tax laws and rates | (1,307) | — | ||||
$370 | $415 | |||||
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Loss before income taxes | $(56,813) | $(35,135) | ||||
Applicable tax rate | 11.85% | 11.85% | ||||
Tax benefit at the applicable tax rate | 6,732 | 4,163 | ||||
Permanent differences | 270 | 458 | ||||
Effect of foreign tax rate differential | 2,587 | 2,062 | ||||
Change in valuation allowance | (7,916) | (6,286) | ||||
Tax rate adjustment | (1,307) | — | ||||
Income tax benefit | $366 | $398 | ||||
Effective tax rate | 0.65% | 1.13% | ||||
TABLE OF CONTENTS
December 31, 2025 | December 31, 2024 | |||||
Deferred tax assets: | ||||||
Intangible assets | $118 | $120 | ||||
Accounts receivable | — | 274 | ||||
Property and equipment | 6 | 13 | ||||
Operating lease liabilities | 288 | — | ||||
Pension liability | 132 | 146 | ||||
Accrued expenses | 202 | 35 | ||||
Other | 542 | 93 | ||||
Net operating loss carry forwards | 32,534 | 23,620 | ||||
Total gross deferred tax assets | $33,822 | $24,301 | ||||
Less valuation allowance | (31,985) | (23,045) | ||||
Net deferred tax assets | $1,837 | $1,256 | ||||
Deferred tax liabilities: | ||||||
Intangible assets | (3,483) | (3,500) | ||||
Other | (854) | (299) | ||||
Total gross deferred liabilities | $(4,338) | $(3,799) | ||||
Net deferred tax liability | $(2,501) | $(2,543) | ||||
Jurisdiction and expiry in: | December 31, 2025 | December 31, 2024 | ||||
Switzerland - One year | $2,334 | $824 | ||||
Switzerland - Two to five years | 111,706 | 78,671 | ||||
Switzerland - More than five years | 52,336 | 43,579 | ||||
United States - No expiry | 50,831 | 29,863 | ||||
Other jurisdictions - No expiry | 3,563 | 2,610 | ||||
Total | $220,770 | $155,547 | ||||
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Net loss | $(56,447) | $(34,737) | ||||
Weighted average of ordinary shares used for basic and diluted loss per share computation(1) | 35,345,300 | 31,351,517 | ||||
Loss per share | ||||||
Basic and diluted | $(1.60) | $(1.11) | ||||
(1) | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Redeemable Series A convertible preferred shares(1) | 6,856,795 | 6,856,795 | ||||
Share options(1) | 892,777 | 315,000 | ||||
Share-based awards(1) | 994,288 | 617,398 | ||||
Total potential dilutive securities not included in loss per share(1) | 8,743,860 | 7,789,193 | ||||
(1) | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
TABLE OF CONTENTS
December 31, 2025 | December 31, 2024 | |||||
Pension benefits | Pension benefits | |||||
Benefit obligation | $(12,333) | $(7,945) | ||||
Fair value of plan assets | 11,207 | 6,716 | ||||
Funded status | $(1,126) | $(1,229) | ||||
Amounts recognized in the balance sheet consist of: | ||||||
Pension liability | (1,126) | (1,229) | ||||
Accumulated other comprehensive gain/(loss) | $374 | $47 | ||||
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Net actuarial (loss)/gain | $327 | $(581) | ||||
$327 | $(581) | |||||
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Pension benefits | Pension benefits | |||||
Net periodic benefit cost recognized | $(884) | $(671) | ||||
TABLE OF CONTENTS
Net actuarial gain | $327 | $(581) | ||||
Total recognized in accumulated other comprehensive gain | 327 | (581) | ||||
Total recognized in net periodic benefit cost and accumulated other comprehensive gain/(loss) | $(557) | $(1,252) | ||||
December 31, 2025 | December 31, 2024 | |||||
Pension benefits | Pension benefits | |||||
Discount rate | 1.3% | 1.1% | ||||
Rate of compensation increase | 1.0% | 1.0% | ||||
Expected long-term rate of return on assets for net periodic pension income | 2.5% | 2.5% | ||||
2025 | 2024 | |||||
Change in benefit obligation: | ||||||
Benefit obligation as of January 1, | $1,229 | $644 | ||||
Interest cost | 107 | 106 | ||||
Service cost | 991 | 661 | ||||
Benefits and administrative expenses paid by employer | (813) | (606) | ||||
Actuarial (gains) losses | (332) | 640 | ||||
Expected return on plan assets | (209) | (161) | ||||
Foreign currency translation | 153 | (55) | ||||
Benefit obligation as of December 31, | $1,126 | $1,229 | ||||
2025 | 2024 | |||||
Fair value of plan assets as of January 1, | $6,716 | $6,679 | ||||
Actual return on plan assets | 935 | 268 | ||||
Contributions by the employer | 813 | 606 | ||||
Contributions by plan participants | 349 | 260 | ||||
Pensions (paid) | (57) | (54) | ||||
Termination Benefits / Withdrawals (paid) | (793) | (1,104) | ||||
Benefits deposited | 2,081 | 528 | ||||
Currency translation | 1,162 | (466) | ||||
Fair value of plan assets as of December 31, | $11,207 | $6,716 | ||||
TABLE OF CONTENTS
Fair value measurements | ||||||
December 31, 2025 | December 31, 2024 | |||||
Equity instruments | $4,440 | $2,321 | ||||
Debt instruments | 3,055 | 2,259 | ||||
Properties not occupied by and not used by the company | 2,694 | 1,617 | ||||
Liquid assets | 233 | 105 | ||||
Others | 784 | 414 | ||||
Total other plan assets at fair value | $11,207 | $6,716 | ||||
Target allocation | ||||||
December 31, 2025 | December 31, 2024 | |||||
Equity instruments | 40% | 35% | ||||
Debt instruments | 27% | 34% | ||||
Properties not occupied by and not used by the company | 24% | 24% | ||||
Liquid assets | 2% | 2% | ||||
Others | 7% | 6% | ||||
Total allocation | 100% | 100% | ||||
Others | |||
Balance as of January 1, 2025 | $414 | ||
Actual return on plan assets | 41 | ||
Purchase sales, settlements, net | 329 | ||
Balance as of December 31, 2025 | $784 | ||
Others | |||
Balance as of January 1, 2024 | $309 | ||
Actual return on plan assets | 19 | ||
Purchase sales, settlements, net | 86 | ||
Balance as of December 31, 2024 | $414 | ||
TABLE OF CONTENTS
Year Ended December 31, | ||||||
2025 | 2024 | |||||
Research and development expense | $409 | $164 | ||||
Selling, general and administrative expense | 13,475 | 5,726 | ||||
Total Share-based compensation expense | $13,884 | $5,890 | ||||
Service-based RSU | ||||||
Number of units(1) | Weighted-average grant date fair value ($, per unit) | |||||
Non-vested as of January 1, 2024 | 78,128 | $6.77 | ||||
Granted | 1,042,632 | 6.77 | ||||
Vested | (425,233) | 6.77 | ||||
Forfeited | (78,128) | 6.77 | ||||
Non-vested as of December 31, 2024 | 617,398 | $6.77 | ||||
Non-vested as of January 1, 2025 | 617,398 | $6.67 | ||||
Granted | 1,115,818 | 14.71 | ||||
Vested | (697,817) | 11.38 | ||||
Forfeited | (41,112) | 6.77 | ||||
Non-vested as of December 31, 2025 | 994,288 | $12.77 | ||||
(1) | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Number of shares(1) | Weighted- Average Exercise Price(1) | Weighted- Average Remaining Contractual Term | Aggregate Intrinsic Value | |||||||||
Outstanding, January 1, 2024 | — | |||||||||||
Granted | 1,711,667 | |||||||||||
Exercised | (1,396,667) | 0.006 | 2 | 9,449 | ||||||||
Outstanding, December 31, 2024 | 315,000 | 0.006 | 2 | 2,133 | ||||||||
Vested and expected to vest, December 2024 | 315,000 | 0.006 | 2 | 2,133 | ||||||||
Outstanding, January 1, 2025 | 315,000 | |||||||||||
Granted | 668,610 | |||||||||||
Exercised | (90,833) | 0.006 | 3 | (1,336) | ||||||||
Outstanding, December 31, 2025 | 892,777 | 0.006 | 3 | 13,130 | ||||||||
Vested and expected to vest, December 2025 | 892,777 | 0.006 | 3 | 13,130 | ||||||||
(1) | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
Unobservable Inputs | Year Ended December 31, 2025 | ||
Expected term in years | 5 | ||
Discount rate | 30% | ||
Terminal growth rate | 2% | ||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Unaudited Condensed Consolidated Balance Sheets | F-38 | ||
Unaudited Condensed Consolidated Statements of Operations | F-40 | ||
Unaudited Condensed Consolidated Statements of Comprehensive Loss | F-41 | ||
Unaudited Condensed Consolidated Statements of Mezzanine Equity and Shareholders’ Equity (Deficit) | F-42 | ||
Unaudited Condensed Consolidated Statements of Cash Flows | F-44 | ||
Notes to Unaudited Condensed Consolidated Financial Statements of vVARDIS Holding AG and Subsidiaries (Unaudited) | F-46 | ||
TABLE OF CONTENTS
June 30, 2026 | December 31, 2025 | |||||
Assets | ||||||
Cash and cash equivalents | $28,974 | $17,470 | ||||
Accounts receivable, net of allowances of $201 and $202, respectively | 7,220 | 3,042 | ||||
Inventories | 10,711 | 8,616 | ||||
Advances to Suppliers | 2,813 | 2,065 | ||||
Prepaid expenses | 5,232 | 624 | ||||
Other current assets | 3,437 | 1,703 | ||||
Receivable – due from related parties | 61 | — | ||||
Total current assets | 58,447 | 33,520 | ||||
Property and equipment, net | 812 | 829 | ||||
Operating lease right-of-use assets | 2,156 | 2,456 | ||||
Intangible assets, net | 29,076 | 31,823 | ||||
Goodwill | 13,123 | 13,387 | ||||
Deferred tax assets | — | — | ||||
Restricted cash | 207 | 211 | ||||
Other non-current assets | 982 | 1,002 | ||||
Total assets | 104,803 | 83,228 | ||||
Liabilities, mezzanine equity and shareholder’s (deficit) equity | ||||||
Accounts payable | $6,876 | $6,857 | ||||
Loans, current - due to related party | — | 1,390 | ||||
Loans, current | 17,204 | — | ||||
Current operating lease liabilities | 512 | 522 | ||||
Deferred revenue, current | 15,000 | 7,500 | ||||
Accrued compensation and benefits | 4,081 | 4,149 | ||||
Accrued operating expenses | 8,900 | 4,482 | ||||
Other current liabilities | 8,613 | 2,373 | ||||
Total current liabilities | 61,186 | 27,273 | ||||
Non-current operating lease liabilities | 1,649 | 1,935 | ||||
Deferred revenue, non-current | — | 7,500 | ||||
Convertible loans, non-current | — | 17,236 | ||||
Loans, non-current | 67,003 | 85,974 | ||||
Liability for pension benefits | 1,119 | 1,126 | ||||
Deferred tax liabilities | 2,042 | 2,501 | ||||
Derivative liabilities, non-current | 31,409 | — | ||||
Total liabilities | 164,408 | 143,545 | ||||
Commitments and contingencies (Note 15) | — | — | ||||
Mezzanine equity: | ||||||
Redeemable Series A convertible preferred shares, CHF 0.006 par value; 6,856,795 shares authorized, issued and outstanding as of June 30, 2026 and December 31, 2025 | 44,472 | 44,472 | ||||
TABLE OF CONTENTS
June 30, 2026 | December 31, 2025 | |||||
Redeemable Series B convertible preferred shares, CHF 0.006 par value; 1,728,390 shares authorized, issued and outstanding as of June 30, 2026 and nil as of December 31, 2025 | 14,425 | — | ||||
Shareholder’s (deficit) equity1: | ||||||
Ordinary shares, CHF 0.006 par value; 72,046,318 shares authorized, 34,186,620 and 31,822,153 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 227 | 209 | ||||
Additional paid-in capital | 140,379 | 126,398 | ||||
Accumulated deficit | (256,322) | (228,515) | ||||
Accumulated other comprehensive loss | (1,576) | (1,748) | ||||
Total shareholders’ deficit attributable to owners of vVARDIS Holding AG | (117,292) | (103,656) | ||||
Non-controlling interests | (1,210) | (1,133) | ||||
Total shareholder’s (deficit) equity | (118,502) | (104,789) | ||||
Total liabilities, mezzanine equity and shareholders’ equity | $104,803 | $83,228 | ||||
1 | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Net revenue | $28,558 | $9,088 | ||||
Cost of goods sold | (3,885) | (4,417) | ||||
Research and development expense | (7,159) | (2,002) | ||||
Selling, general and administrative expense | (35,064) | (26,750) | ||||
Loss from operations | (17,550) | (24,081) | ||||
Interest expense | (9,015) | (4,061) | ||||
Loss on loans measured at fair value | (1,205) | (1,474) | ||||
Gain on loan conversion | 1,613 | — | ||||
Loss due to change in the fair value of derivative liabilities | (8) | — | ||||
Loss on term loan extinguishment | (1,580) | (1,245) | ||||
Other income / (expense), net | (412) | (1,169) | ||||
Loss before income taxes | (28,157) | (32,030) | ||||
Income tax benefit / (expense) | 350 | (26) | ||||
Net loss | $(27,807) | $(32,057) | ||||
Net loss attributable to: | ||||||
Owners of vVARDIS Holding AG | (27,807) | (32,057) | ||||
Non-controlling interests | — | — | ||||
Loss per ordinary share | ||||||
Basic1 | $(0.70) | $(0.93) | ||||
Diluted1 | $(0.70) | $(0.93) | ||||
Weighted average shares outstanding | ||||||
Basic and diluted | 39,948,137 | 34,619,819 | ||||
1 | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Net loss | $(27,807) | $(32,057) | ||||
Other comprehensive (loss)/gain, net of tax: | ||||||
Foreign currency translation adjustments, net of tax, $0 | 56 | 147 | ||||
Net actuarial gain on defined benefit pension plans, net of tax, $0 | 38 | 291 | ||||
Total other comprehensive (loss)/gain | $94 | $439 | ||||
Comprehensive loss | $(27,713) | $(31,618) | ||||
Comprehensive loss attributable to: | ||||||
Owners of vVARDIS Holding AG | (27,634) | (31,757) | ||||
Non-controlling interests | (77) | 139 | ||||
TABLE OF CONTENTS
Redeemable Series A Convertible Preferred Shares | Redeemable Series B Convertible Preferred Shares | Ordinary Shares | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive gain/(loss) | Total shareholders’ equity (deficit) | Non- controlling interests | Total equity (deficit) | ||||||||||||||||||||||||||||||||||
Shares1 | Par value | Amount | Shares1 | Par value | Amount | Shares1 | Par value | |||||||||||||||||||||||||||||||||||
Balance as of January 1, 2026 | 6,856,795 | $45 | $44,472 | — | $— | $— | 31,822,153 | $209 | $126,398 | $(228,515) | $(1,748) | $(103,656) | $(1,133) | $(104,789) | ||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | — | — | — | — | (27,807) | — | (27,807) | — | (27,807) | ||||||||||||||||||||||||||||
Other comprehensive loss | — | — | — | — | — | — | — | — | — | — | 171 | 171 | (77) | 94 | ||||||||||||||||||||||||||||
Share-based compensation | — | — | — | — | — | — | — | — | 4,007 | — | — | 4,007 | — | 4,007 | ||||||||||||||||||||||||||||
Issuance of ordinary shares | — | — | — | — | — | — | 2,197,361 | 17 | — | — | — | 17 | — | 17 | ||||||||||||||||||||||||||||
Issuance of preferred shares (net of derivate liability and issuance costs) | — | — | — | 1,129,820 | 8 | 10,594 | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||
Issuance of warrants | — | — | — | — | — | — | — | — | 8,675 | — | — | 8,675 | — | 8,675 | ||||||||||||||||||||||||||||
Conversion of convertible loans | — | — | — | 598,570 | 5 | 5,445 | 167,106 | 1 | 1,300 | — | — | 1,301 | — | 1,301 | ||||||||||||||||||||||||||||
Equity issuance cost | — | — | — | — | — | (1,614) | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||
Balance as of June 30, 2026 | 6,856,795 | $45 | $44,472 | 1,728,390 | $13 | $14,425 | 34,186,620 | $227 | $140,379 | $(256,322) | $(1,576) | $(117,292) | $(1,210) | $(118,502) | ||||||||||||||||||||||||||||
1 | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Redeemable Series A Convertible Preferred Shares | Redeemable Series B Convertible Preferred Shares | Ordinary Shares | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive gain/(loss) | Total shareholder’s equity (deficit) | Non- controlling interests | |||||||||||||||||||||||||||||||||||
Shares1 | Par value | Amount | Shares1 | Par value | Amount | Shares1 | Par value | Total equity (deficit) | ||||||||||||||||||||||||||||||||||
Balance as of January 1, 2025 | 6,856,795 | $45 | $44,472 | — | — | — | 31,731,320 | $208 | $97,518 | $(172,068) | $(603) | $(74,945) | $(1,028) | $(75,973) | ||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | — | — | — | — | (32,057) | — | (32,057) | — | (32,057) | ||||||||||||||||||||||||||||
Other comprehensive gain | — | — | — | — | — | — | — | — | — | — | 300 | 300 | 139 | 439 | ||||||||||||||||||||||||||||
Share-based compensation | — | — | — | — | — | — | — | — | 6,358 | — | — | 6,358 | — | 6,358 | ||||||||||||||||||||||||||||
Issuance of warrants | — | — | — | — | — | — | — | — | 15,001 | — | — | 15,001 | — | 15,001 | ||||||||||||||||||||||||||||
Issuance of ordinary shares | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||
Balance as of June 30, 2025 | 6,856,795 | $45 | $44,472 | — | — | — | 31,731,320 | $208 | $118,877 | $(204,125) | $(303) | $(85,343) | $(890) | $(86,233) | ||||||||||||||||||||||||||||
1 | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Cash flows from operating activities: | ||||||
Net loss | $(27,807) | $(32,057) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Adjustments to fair value in debt | 1,202 | 1,337 | ||||
Gain on loan conversion | (1,613) | — | ||||
Loss / (gain) due to change in the fair value of derivative liabilities | 8 | — | ||||
Loss on term loan extinguishment | 1,574 | 1,429 | ||||
Depreciation and amortization | 2,293 | 1,815 | ||||
Amortization of debt issuance costs | 1,584 | 283 | ||||
Deferred income taxes | (414) | 42 | ||||
Pension costs / (benefits) | 15 | (222) | ||||
Non-cash interest expense | 3,976 | 2,499 | ||||
Share-based compensation | 4,056 | 6,198 | ||||
Non-cash lease expense | 259 | (52) | ||||
Unrealized gain / (loss) on foreign exchange | 1,707 | (2,370) | ||||
Changes in operating assets and liabilities | ||||||
Decrease (increase) in accounts receivable | (4,437) | (1,130) | ||||
Decrease (increase) in inventories | (2,319) | 2,085 | ||||
Decrease (increase) in advances to suppliers | (811) | (1,533) | ||||
Decrease (increase) in prepaid expenses | (4,562) | (87) | ||||
Decrease (increase) in other current assets | (1,671) | 176 | ||||
Increase (decrease) in accounts payable | 27 | (1,425) | ||||
Increase (decrease) in accrued compensation and benefit | (3) | (274) | ||||
Increase (decrease) in accrued operating expenses | 4,624 | (233) | ||||
Increase (decrease) in other current liabilities | 6,247 | 716 | ||||
Increase (decrease) in operating lease liabilities | (253) | 48 | ||||
Net cash used in operating activities | (16,317) | (22,755) | ||||
Cash flows from investing activities: | ||||||
Acquisition of property and equipment | — | (78) | ||||
Acquisition of intangible assets | — | (169) | ||||
Net cash used in investing activities | — | (247) | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of shareholder loans | — | 57 | ||||
Proceeds from issuance of term loans | — | 66,453 | ||||
Proceeds from issuance of warrants | — | 15,715 | ||||
Repayment of long-term debt | — | (48,000) | ||||
Repayment of convertible loans | (66) | — | ||||
Repayment of shareholder loans | (65) | — | ||||
Debt issuance costs | — | (2,250) | ||||
Equity issuance costs | (1,612) | — | ||||
Proceeds from issuance of share capital | 11 | — | ||||
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Proceeds from issuance of Series B preferred shares | 31,656 | — | ||||
Net cash provided by financing activities | 29,924 | 31,975 | ||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (2,107) | 3,825 | ||||
Cash, cash equivalents and restricted cash: | ||||||
Net change during the period | 11,500 | 12,798 | ||||
Balance, beginning of period | 17,681 | 2,405 | ||||
Cash, cash equivalents and restricted cash at end of period | 29,181 | 15,203 | ||||
Supplemental disclosure of non-cash investing and financing activity: | ||||||
Conversion of 2027 Convertible Loan into Series B convertible preferred shares | 16,837 | — | ||||
Conversion of management convertible loans into ordinary shares | 1,280 | — | ||||
Bifurcation of embedded derivative liabilities from Series B convertible preferred shares at issuance | 31,401 | — | ||||
June 30, 2026 | June 30, 2025 | |||||
Total presented in the Statements of Cash Flows | $29,181 | $15,203 | ||||
Of which in the Balance Sheets: | ||||||
- Cash and cash equivalents | 28,974 | 15,119 | ||||
- Restricted cash | 207 | 84 | ||||
Total | $29,181 | $15,203 | ||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
• | Level 1—Quoted prices in active markets for identical assets and liabilities. |
• | Level 2—Quoted prices in active markets for similar assets and liabilities, or other inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. |
• | Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flows methodologies, and similar techniques that use significant unobservable inputs. |
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Net revenue | $28,558 | $9,088 | ||||
Cost of goods sold | (3,582) | (4,235) | ||||
Logistical expenses | (303) | (182) | ||||
Research and development expense | (7,159) | (2,002) | ||||
SG&A expenses - people costs* | (19,876) | (16,082) | ||||
SG&A expenses - non-people costs** | (8,037) | (5,617) | ||||
SG&A expenses – restructuring and other advisory costs*** | (605) | — | ||||
Marketing expenses | (4,253) | (3,236) | ||||
Depreciation and amortization | (2,293) | (1,815) | ||||
Other income / (expense), net | (412) | (1,169) | ||||
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Interest expense | (9,015) | (4,061) | ||||
Gain / (loss) on loans measured at fair value | 408 | (1,474) | ||||
Loss due to change in the fair value of derivative liabilities | (8) | — | ||||
Loss on term loan extinguishment | (1,580) | (1,245) | ||||
Income tax benefit / (expense) | 350 | (26) | ||||
Net loss | $(27,807) | $(32,057) | ||||
* | Related to personnel expenses such as payroll, bonus and other employee benefits |
** | Related to professional fees and services and office related cost (including rent, utilities and other general administrative expenses) |
*** | Represents costs incurred in connection with restructuring initiatives, including legal, advisory and employee-related costs, as well as advisory costs related to other strategic activities |
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Net revenues: | ||||||
United States | $27,138 | $7,972 | ||||
Italy | 533 | 261 | ||||
United Kingdom | 442 | — | ||||
Switzerland | 317 | 635 | ||||
Others | 128 | 220 | ||||
Total | $28,558 | $9,088 | ||||
June 30, 2026 | December 31, 2025 | |||||
Accounts receivable, gross | $7,421 | $3,244 | ||||
Less: Allowance for credit losses | (201) | (202) | ||||
Accounts receivable, net | $7,220 | $3,042 | ||||
June 30, 2026 | December 31, 2025 | |||||
Balance, beginning of the period | $202 | $176 | ||||
Expected credit losses | — | 17 | ||||
Write-offs | — | — | ||||
Foreign exchange effects | (1) | 9 | ||||
Balance, end of the period | $201 | $202 | ||||
TABLE OF CONTENTS
June 30, 2026 | December 31, 2025 | |||||
Raw materials and components | $6,142 | $3,534 | ||||
Work in process | 2,875 | 3,176 | ||||
Finished goods | 2,116 | 2,185 | ||||
Total inventories, gross | $11,133 | $8,895 | ||||
Less: Provision for excess & obsolescence | (422) | (279) | ||||
Total inventories, net | $10,711 | $8,616 | ||||
As of June 30, 2026 | ||||||||||||
Weighted Average Remaining Lives | Cost | Accumulated Amortization | Net | |||||||||
Finite-lived Intangible Assets: | ||||||||||||
Trademark | 6 yrs | $8,198 | $(4,601) | $3,597 | ||||||||
Patents | 7 yrs | 53,200 | (29,534) | 23,666 | ||||||||
Software | 4 yrs | 2,223 | (411) | 1,813 | ||||||||
Total intangible assets | $63,621 | $(34,546) | $29,076 | |||||||||
As of December 31, 2025 | ||||||||||||
Weighted Average Remaining Lives | Cost | Accumulated Amortization | Net | |||||||||
Finite-lived Intangible Assets: | ||||||||||||
Trademark | 7 yrs | $8,363 | $(4,275) | $4,088 | ||||||||
Patents | 8 yrs | 54,270 | (28,602) | 25,668 | ||||||||
Software | 5 yrs | 2,268 | (201) | 2,067 | ||||||||
Total intangible assets | $64,901 | $(33,078) | $31,823 | |||||||||
TABLE OF CONTENTS
Level | June 30, 2026 | December 31, 2025 | |||||||
Financial Assets: | |||||||||
Cash and cash equivalents | 1 | 28,974 | 17,470 | ||||||
Restricted cash | 2 | 207 | 211 | ||||||
Accounts receivable | 2 | 7,220 | 3,042 | ||||||
Other current assets | 2 | 3,437 | 1,703 | ||||||
Receivable – due from related parties | 2 | 61 | — | ||||||
Financial liabilities: | |||||||||
Accounts payable | 2 | 6,876 | 6,857 | ||||||
Loans, current | 2 | 17,204 | — | ||||||
Loans, non-current | 2 | 67,003 | 85,974 | ||||||
Loans, current - due to related party | 2 | — | 1,390 | ||||||
Convertible Loans, non-current | 3 | — | 17,236 | ||||||
Derivative liabilities, non-current | 3 | 31,409 | — | ||||||
Other current liabilities and accrued expenses (Note 9) | 2 | 21,594 | 11,004 | ||||||
TABLE OF CONTENTS
Valuation Assumptions | April 22, 2026 (issuance) | June 30, 2026 | ||||
Expected volatility | 46% | 42% | ||||
Risk-free interest rate | 0.02% | -0.01% | ||||
Dividend yield | 0% | 0% | ||||
Expected term (in years) | 0.7 | 0.8 | ||||
TABLE OF CONTENTS
Derivative liabilities | June 30, 2026 | December 31, 2025 | ||||
Balance, beginning of the period | $— | $— | ||||
Additions to derivative liabilities | 31,401 | — | ||||
Loss due to change in the fair value of derivative liabilities | 8 | — | ||||
Balance, end of the period | $31,409 | $— | ||||
Yield | Maturities | June 30, 2026 | December 31, 2025 | |||||||||
2026 Convertible Loan 6% - due to related party | 6% | Dec – 2026 | $— | $320 | ||||||||
2026 Convertible Loan 4% - due to related party | 4% | Dec – 2026 | — | 1,009 | ||||||||
2027 Convertible Loan | 7% | Jun – 2027 | — | 17,236 | ||||||||
Shareholder Loan – due to related party | 8% | — | 61 | |||||||||
2026 Term Loan Tranche I* | 8% | Jun – 2027 | 11,568 | 11,135 | ||||||||
2026 Term Loan Tranche II* | 8% | Jun – 2027 | 5,636 | 5,419 | ||||||||
2030 Term Loan Tranche I | 12% | Feb – 2030 | 37,485 | 36,300 | ||||||||
2030 Term Loan Tranche II | 17% | Feb – 2030 | 55,125 | 52,179 | ||||||||
Less: unamortized discounts and issuance costs | (25,607) | (19,059) | ||||||||||
Total loans | $84,207 | $104,600 | ||||||||||
Less: current maturities | (17,204) | (1,390) | ||||||||||
Total loans, non-current | $67,003 | $103,210 | ||||||||||
* | As of December 31, 2025, 2026 Term Loan Tranche I and 2026 Term Loan Tranche II had contractual maturities of August 2026 and December 2026, respectively. However, in January 2026, both maturity dates were extended to June 2027, with no other material modifications to the terms of the agreements. Accordingly, as of December 31, 2025, the Company classified these obligations as non-current based on its intent and ability to refinance the debt on a long-term basis, as evidenced by the post-balance-sheet-date maturity extension. As of June 30, 2026, these obligations are classified as current because the extended June 2027 maturity date falls within twelve months of the balance sheet date. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
2027 | — | ||
2028 | — | ||
2029 | — | ||
2030 | 92,610 | ||
Thereafter | — | ||
Total | $92,610 | ||
June 30, 2026 | December 31, 2025 | |||||
Accrued compensation and benefits | ||||||
Accrued bonus expense | $1,951 | $3,018 | ||||
Accrued other personnel expenses | 2,130 | 1,131 | ||||
Total accrued compensation and benefits | $4,081 | $4,149 | ||||
Accrued operating expenses | ||||||
Accrued consulting and other services | $8,288 | $2,455 | ||||
Accrued marketing expenses | 477 | 514 | ||||
Customer credit balance | 135 | 1,513 | ||||
Total accrued operating expenses | $8,900 | $4,482 | ||||
Other current liabilities | ||||||
Accrued rebate | $5,359 | $1,358 | ||||
Accrued inventory purchases | 2,905 | 1,015 | ||||
Other current liabilities | 349 | — | ||||
Total Other current liabilities | $8,613 | $2,373 | ||||
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Net loss | $(27,807) | $(32,057) | ||||
Weighted average of ordinary shares used for basic and diluted loss per share computation1 | 39,948,137 | 34,619,819 | ||||
Loss per share | ||||||
Basic and diluted | $(0.70) | $(0.93) | ||||
1 | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Redeemable Series A convertible preferred shares1 | 6,856,795 | 6,856,795 | ||||
Redeemable Series B convertible preferred shares1 | 1,728,390 | — | ||||
Share options1 | 192,065 | 915,277 | ||||
Share-based awards1 | 268,868 | 1,436,062 | ||||
Total potential dilutive securities not included in loss per share | 9,046,118 | 9,208,133 | ||||
1 | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
Shares Authorized1 | Shares Issued and Outstanding1 | Issuance Price Per Share1 | Carrying Value | Aggregate Liquidation Preference | |||||||||||||||||
As of June 30, 2026 | |||||||||||||||||||||
Series A Convertible Preferred Shares | 6,856,795 | 6,856,795 | CHF | 6.00 | $44,472 | CHF | 64,204 | ||||||||||||||
Series B Convertible Preferred Shares | 1,728,390 | 1,728,390 | 22.04 | 14,425 | 114,271 | ||||||||||||||||
Total | 8,585,185 | 8,585,185 | $58,897 | 178,475 | |||||||||||||||||
1 | Amounts have been retrospectively adjusted to account for the share split that was approved on August 24, 2026, and effective September 15, 2026. |
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Interest cost | $86 | $45 | ||||
Service cost | 616 | 473 | ||||
Expected return on plan assets | (156) | (87) | ||||
Gain recognized in net periodic pension cost | (3) | (3) | ||||
Total Net periodic benefit costs | $543 | $428 | ||||
Six Months Ended June 30, | ||||||
2026 | 2025 | |||||
Research and development expense | $204 | $198 | ||||
Selling, general and administrative expense | 3,803 | 6,160 | ||||
Total Share-based compensation expense | $4,007 | $6,358 | ||||
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS

TABLE OF CONTENTS
Item 6. | Indemnification of Directors and Officers |
TABLE OF CONTENTS
Item 7. | Recent Sales of Unregistered Securities |
Name or Class of Purchaser | Date of Issuance | Title of Security | Number, or Principal Amount, of Securities | Consideration(1) | ||||||||
Founders | December 2023 | Ordinary shares | 5,761,811 | CHF 34,640,016.43 ($43,687,749) | ||||||||
Founders | December 2023 | Ordinary shares | 3,761,828 | CHF 22,616,109.59 ($28,523,281) | ||||||||
Other Investor | December 2023 | Ordinary shares | 499,997 | CHF 2,384,750.68 ($3,007,631) | ||||||||
Institutional investor | December 2023 | Ordinary shares | 80,346 | CHF 483,050.00 ($609,219) | ||||||||
Directors, officers and employees | January to December 2024 | Options | 1,711,667 | —(2) | ||||||||
Directors, officers and employees | January to December 2024 | RSUs | 1,042,632 | —(2) | ||||||||
Directors, officers and employees | January to December 2025 | Options | 668,610 | —(2) | ||||||||
Directors, officers and employees | January to December 2025 | RSUs | 1,115,818 | —(2) | ||||||||
Institutional investor | June 2024 | Warrants | CHF 9,372.49 ($11,820) | |||||||||
Institutional investor | August 2024 | Promissory note | $10,000,000 | — | ||||||||
Institutional investor | December 2024 | Promissory note | $5,000,000 | — | ||||||||
Institutional investor | February 2025 | Promissory note | $35,000,000 | — | ||||||||
Institutional investor | February 2025 | Warrants | 727,990 | —(3) | ||||||||
Institutional investor | June 2025 | Warrants | 1,090,938 | —(3) | ||||||||
Institutional investor | January 2026 | Warrants | 697,955 | —(3) | ||||||||
Institutional investor | April 2026 | Class B preferred shares | 598,570 | CHF 13,191,854.79 ($16,637,476) | ||||||||
Employee | April 2026 | Ordinary shares | 33,333 | CHF 200,400.00 ($252,743) | ||||||||
Employee | April 2026 | Ordinary shares | 133,773 | CHF 804,246.58 ($1,014,310) | ||||||||
Institutional investor | April 2026 | Class B preferred shares | 1,129,816 | CHF 24,900,000.00 ($31,403,708) | ||||||||
(1) | Solely for presentation purposes, where applicable, the applicable consideration paid has been converted into U.S. dollars using the USD/CHF exchange rate of 0.7929 (i.e., $1.2612 per CHF) in effect as of December 31, 2025, based on the Euro Foreign Exchange Reference Rates published by the European Central Bank on December 31, 2025. |
(2) | Refers to equity awards granted at various times pursuant to our existing equity incentive plans, as more fully described under “Management—Equity Incentive Plans” in the prospectus which forms part of this registration statement. |
(3) | Refers to warrants to acquire our ordinary shares issued to OrbiMed in connection with entry into, or amendment to, the OrbiMed Credit Agreement, as more fully described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Indebtedness” in the prospectus which forms part of this registration statement. |
TABLE OF CONTENTS
Item 8. | Exhibits and Financial Statement Schedules |
(a) | Exhibits. |
Exhibit No. | Description | ||
1.1 | Form of Underwriting Agreement. | ||
3.1** | Form of Amended and Restated Articles of Association of vVARDIS Holding AG, to be in effect immediately prior to the completion of this offering. | ||
5.1 | Opinion of Homburger AG, Swiss counsel of vVARDIS Holding AG, as to the validity of the Class A ordinary shares. | ||
10.1** | Form of Shareholders’ Agreement by and among vVARDIS Holding AG and the Founders. | ||
10.2.1** | Credit Agreement and Guaranty, dated as of February 6, 2025, by and among vVARDIS AG, vVARDIS Holding AG, certain subsidiaries of vVARDIS Holding AG from time to time party thereto, the Lenders from time to time party thereto and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders.†# | ||
10.2.2** | Amendment No. 1 to Credit Agreement and Guaranty, dated as of June 30, 2025, by and among vVARDIS AG, vVARDIS Holding AG, certain subsidiaries of vVARDIS Holding AG from time to time party thereto, the Lenders from time to time party thereto and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders.†# | ||
10.2.3** | Waiver and Amendment No. 2 to Credit Agreement and Guaranty, dated as of November 28, 2025, by and among vVARDIS AG, vVARDIS Holding AG, certain subsidiaries of vVARDIS Holding AG from time to time party thereto, the Lenders from time to time party thereto and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders.†# | ||
10.2.4** | Amendment No. 3 to Credit Agreement and Guaranty, dated as of January 9, 2026, by and among vVARDIS AG, vVARDIS Holding AG, certain subsidiaries of vVARDIS Holding AG from time to time party thereto, the Lenders from time to time party thereto and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders.†# | ||
10.2.5** | Acknowledgment, Consent and Amendment No. 4 to Credit Agreement and Guaranty, dated as of February 27, 2026, by and among vVARDIS AG, vVARDIS Holding AG, certain subsidiaries of vVARDIS Holding AG from time to time party thereto, the Lenders from time to time party thereto and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders.†# | ||
10.2.6** | Waiver and Amendment No. 5 to Credit Agreement and Guaranty, dated as of September 14, 2026, by and among vVARDIS AG, vVARDIS Holding AG, certain subsidiaries of vVARDIS Holding AG party thereto, the Lenders party thereto, and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders.†# | ||
10.3.1** | Secured Promissory Note, issued on August 19, 2024, by vVARDIS Inc. to Henry Schein, Inc.†# | ||
10.3.2** | Amendment No. 1 to Secured Promissory Note (August 19, 2024), dated as of January 13, 2026, by and between vVARDIS Inc. and Henry Schein, Inc. | ||
10.4** | Third Amended and Restated Distribution Agreement, dated as of September 29, 2026, between vVARDIS Inc., vVARDIS Holding AG and Henry Schein, Inc.†# | ||
10.5.1** | Secured Promissory Note, issued on December 20, 2024, by vVARDIS Inc. to Henry Schein, Inc. †# | ||
10.5.2** | Amendment No. 1 to Secured Promissory Note issued on December 20, 2024, dated as of January 13, 2026, by and between vVARDIS Inc. and Henry Schein, Inc. | ||
10.6.1** | vVARDIS Holding AG 2024 Equity Incentive Plan, adopted on March 28, 2024.§ | ||
TABLE OF CONTENTS
Exhibit No. | Description | ||
10.6.2** | First Amendment to the vVARDIS Holding AG 2024 Equity Incentive Plan, adopted on November 19, 2025.§ | ||
10.7.1** | vVARDIS Holding AG 2024 Share Option Plan, adopted on March 28, 2024.§# | ||
10.7.2** | vVARDIS Holding AG 2025 Share Option Plan, adopted on November 19, 2025.§# | ||
10.8** | Form of Indemnification Agreement with directors and officers entered into in connection with this offering.§ | ||
10.9** | vVARDIS Holding AG 2026 Equity Incentive Plan.§ | ||
21.1** | List of Subsidiaries. | ||
23.1 | Consent of Deloitte AG. | ||
23.2 | Consent of Homburger AG (included in Exhibit 5.1). | ||
24.1** | Powers of Attorney (included on signature page to the original filing of the registration statement). | ||
99.1** | Consent of Steve Swift | ||
99.2** | Consent of Frank Williams | ||
99.3** | Consent of Elizabeth Coddington | ||
107 | Filing Fee Table. | ||
** | Filed previously |
§ | Indicates management contract or compensatory plan or arrangement. |
† | Portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that (i) the omitted information is not material and (ii) the omitted information is the type that the registrant treats as private or confidential. |
# | Certain annexes to this agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Registrant will furnish copies of such annexes to the U.S. Securities and Exchange Commission upon request. |
(b) | Financial Statement Schedules. |
Item 9. | Undertakings |
(1) | For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. |
(2) | For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
TABLE OF CONTENTS
vVARDIS HOLDING AG | |||||||||
By: | /s/ Haley Abivardi | ||||||||
Name: | Haley Abivardi | ||||||||
Title: | Co-Chief Executive Officer, Co-Founder & Co-Chair | ||||||||
By: | /s/ Goly Abivardi | ||||||||
Name: | Goly Abivardi | ||||||||
Title: | Co-Chief Executive Officer, Co-Founder & Co-Chair | ||||||||
Name | Title | Date | ||||||||
/s/ Haley Abivardi | Co-Chief Executive Officer, Co-Founder & Co-Chair (Principal Executive Officer) | November 12, 2026 | ||||||||
Haley Abivardi | ||||||||||
/s/ Goly Abivardi | Co-Chief Executive Officer, Co-Founder & Co-Chair (Principal Executive Officer) | November 12, 2026 | ||||||||
Goly Abivardi | ||||||||||
/s/ Thomas Rondot | Chief Financial Officer & Chief People Officer (Principal Financial Officer and Principal Accounting Officer) | November 12, 2026 | ||||||||
Thomas Rondot | ||||||||||
* | Director | November 12, 2026 | ||||||||
Juergen Stark | ||||||||||
* | Director | November 12, 2026 | ||||||||
Clifford zur Nieden | ||||||||||
*/s/ Haley Abivardi | |||
Haley Abivardi, as Attorney-in-Fact | |||
TABLE OF CONTENTS
VVARDIS INC., as Authorized U.S. Representative | ||||||
By: | /s/ Keith Koford | |||||
Name: Keith Koford | ||||||
Title: General Counsel | ||||||

